Jump to content

MDMA

Page semi-protected
From Wikipedia, the free encyclopedia
(Redirected from Xtac)

For other uses, see MDMA (disambiguation). Not to be confused with MDA (drug); EDMA; NMDA; or 2,3-MDMA.

MDMA
INN: Midomafetamine[1]
MDMA structure
Ball-and-stick model of an MDMA molecule
Clinical data
Pronunciationmethylenedioxy­methamphetamine:
/ˌmɛθɪliːndaɪˈɒksi/
/ˌmɛθæmˈfɛtəmiːn/
Other names3,4-MDMA; Ecstasy (E, X, XTC); Midomafetamine; Molly; Mandy;[2][3] Pingers/Pingas[4]
AHFS/Drugs.comMDMA
Dependence
liability		Physical: Not typical[5]
Psychological: Moderate[6]
Addiction
liability		Low–moderate[7][8][9]
Routes of
administration		Common: By mouth[10]
Uncommon: Insufflation,[10] inhalation,[10] injection,[10][11] rectal
Drug classEmpathogen–entactogen; Stimulant
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
BioavailabilityOral: Unknown[13]
Protein bindingUnknown[14]
MetabolismLiver, CYP450 extensively involved, including CYP2D6
MetabolitesMDA, HMMA, HMA, HHMA, HHA, THMA, THA, MDP2P, MDOH[15]
Onset of actionOral: 30–45 min[13]
Elimination half-life
  • MDMA: 8.7 (range 4.6–16) hours[16][17]
  • (S)-MDMA: 5.1 (range 3.5–7.4) hours[16]
  • (R)-MDMA: 11 (range 5.1–24) hours[16]
Duration of action4–6 hours[8][13]
ExcretionKidney
Identifiers
  • (RS)-1-(1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H15NO2
Molar mass193.246 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
Density1.1 g/cm3
Boiling point105 °C (221 °F) at 0.4 mmHg (experimental)
  • CC(NC)CC1=CC=C(OCO2)C2=C1
  • InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3 checkY
  • Key:SHXWCVYOXRDMCX-UHFFFAOYSA-N checkY
  (verify)

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy (tablet form), and molly (crystal form),[18][19] is an empathogen–entactogenic drug with stimulant and minor psychedelic properties.[17][20][21] In studies, it has been used alongside psychotherapy in the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autism spectrum disorder.[22][23][24] The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure.[21][25] When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours.[13][26]

MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch.[27] It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s.[25][26] MDMA is commonly associated with dance parties, raves, and electronic dance music.[28] Tablets sold as ecstasy may be mixed with other substances such as ephedrine, amphetamine, and methamphetamine.[25] In 2016, about 21 million people between the ages of 15 and 64 used ecstasy (0.3% of the world population).[29] This was broadly similar to the percentage of people who use cocaine or amphetamines, but lower than for cannabis or opioids.[29] In the United States, as of 2017, about 7% of people have used MDMA at some point in their lives and 0.9% have used it in the last year.[30] The lethal risk from one dose of MDMA is estimated to be from 1 death in 20,000 instances to 1 death in 50,000 instances.[31]

Short-term adverse effects include grinding of the teeth, blurred vision, sweating, and a rapid heartbeat,[25] and extended use can also lead to addiction, memory problems, paranoia, and difficulty sleeping. Deaths have been reported due to increased body temperature and dehydration. Following use, people often feel depressed and tired, although this effect does not appear in clinical use, suggesting that it is not a direct result of MDMA administration.[25][32] MDMA acts primarily by increasing the release of the neurotransmitters serotonin, dopamine, and norepinephrine in parts of the brain.[25][26] It belongs to the substituted amphetamine classes of drugs.[10][33] MDMA is structurally similar to mescaline (a psychedelic), methamphetamine (a stimulant), as well as endogenous monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine.[34]

MDMA has limited approved medical uses in a small number of countries,[35] but is illegal in most jurisdictions.[36] In the United States, the Food and Drug Administration (FDA) is evaluating the drug for clinical use as of 2021.[37] Canada has allowed limited distribution of MDMA upon application to and approval by Health Canada.[38][39] In Australia, it may be prescribed in the treatment of PTSD by specifically authorised psychiatrists.[40]

Effects

In general, MDMA users report feeling the onset of subjective effects within 30 to 60 minutes of oral consumption and reaching peak effect at 75 to 120 minutes, which then plateaus for about 3.5 hours.[41] The desired short-term psychoactive effects of MDMA have been reported to include:

The experience elicited by MDMA depends on the dose, setting, and user.[8] The variability of the induced altered state is lower compared to other psychedelics. For example, MDMA used at parties is associated with high motor activity, reduced sense of identity, and poor awareness of surroundings. Use of MDMA individually or in small groups in a quiet environment and when concentrating, is associated with increased lucidity, concentration, sensitivity to aesthetic aspects of the environment, enhanced awareness of emotions, and improved capability of communication.[15][43] In psychotherapeutic settings, MDMA effects have been characterized by infantile ideas, mood lability, and memories and moods connected with childhood experiences.[43][44]

MDMA has been described as an "empathogenic" drug because of its empathy-producing effects.[45][46] Results of several studies show the effects of increased empathy with others.[45] When testing MDMA for medium and high doses, it showed increased hedonic and arousal continuum.[47][48] The effect of MDMA increasing sociability is consistent, while its effects on empathy have been more mixed.[49]

Use

Recreational

MDMA is often considered the drug of choice within the rave culture and is also used at clubs, festivals, and house parties.[15] In the rave environment, the sensory effects of music and lighting are often highly synergistic with the drug. The psychedelic amphetamine quality of MDMA offers multiple appealing aspects to users in the rave setting. Some users enjoy the feeling of mass communion from the inhibition-reducing effects of the drug, while others use it as party fuel because of the drug's stimulatory effects.[50] MDMA is used less often than other stimulants, typically less than once per week.[51]

MDMA is sometimes taken in conjunction with other psychoactive drugs such as LSD,[52] psilocybin mushrooms, 2C-B, and ketamine. The combination with LSD is called "candy-flipping".[52] The combination with 2C-B is called "nexus flipping". For this combination, most people take the MDMA first, wait until the peak is over, and then take the 2C-B.[53]

MDMA is often co-administered with alcohol, methamphetamine, and prescription drugs such as SSRIs with which MDMA has several drug-drug interactions.[54][55][56] Three life-threatening reports of MDMA co-administration with ritonavir have been reported;[57] with ritonavir having severe and dangerous drug-drug interactions with a wide range of both psychoactive, anti-psychotic, and non-psychoactive drugs.[58]

Medical

See also: MDMA § Research directions, and MDMA-assisted psychotherapy

As of 2023, MDMA therapies have only been approved for research purposes, with no widely accepted medical indications,[10][59][60] although this varies by jurisdiction. Before it was widely banned, it saw limited use in psychotherapy.[8][10][61] In 2017 the United States Food and Drug Administration (FDA) granted breakthrough therapy designation for MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD),[62][63] with some preliminary evidence that MDMA may facilitate psychotherapy efficacy for PTSD.[64][65] Pilot studies indicate that MDMA-assisted psychotherapy may be beneficial in treating social anxiety in autistic adults.[23][24] In these pilot studies, the vast majority of participants reported increased feelings of empathy that persisted after the therapy sessions.[66]

Other

Small doses of MDMA are used by some religious practitioners as an entheogen to enhance prayer or meditation.[67] MDMA has been used as an adjunct to New Age spiritual practices.[68]

Forms

MDMA has become widely known as ecstasy (shortened "E", "X", or "XTC"), usually referring to its tablet form, although this term may also include the presence of possible adulterants or diluents. The UK term "mandy" and the US term "molly" colloquially refer to MDMA in a crystalline powder form that is thought to be free of adulterants.[2][3][69] MDMA is also sold in the form of the hydrochloride salt, either as loose crystals or in gelcaps.[70][71] MDMA tablets can sometimes be found in a shaped form that may depict characters from popular culture, likely for deceptive reasons.[clarification needed] These are sometimes collectively referred to as "fun tablets".[72][73]

Partly due to the global supply shortage of sassafras oil—a problem largely assuaged by use of improved or alternative modern methods of synthesis—the purity of substances sold as molly have been found to vary widely. Some of these substances contain methylone, ethylone, MDPV, mephedrone, or any other of the group of compounds commonly known as bath salts, in addition to, or in place of, MDMA.[3][69][70][71] Powdered MDMA ranges from pure MDMA to crushed tablets with 30–40% purity.[10] MDMA tablets typically have low purity due to bulking agents that are added to dilute the drug and increase profits (notably lactose) and binding agents.[10] Tablets sold as ecstasy sometimes contain 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA), other amphetamine derivatives, caffeine, opiates, or painkillers.[8] Some tablets contain little or no MDMA.[8][10][74] The proportion of seized ecstasy tablets with MDMA-like impurities has varied annually and by country.[10] The average content of MDMA in a preparation is 70 to 120 mg with the purity having increased since the 1990s.[8]

MDMA is usually consumed by mouth. It is also sometimes snorted.[25]

Image of Ecstasy tablets
Ecstasy tablets which may contain MDMA
Image of a chunk of impure MDMA
A salt of MDMA (typically white) with impurities, resulting in a tan discoloration
1 gram crushed MDMA crystals
Crushed MDMA (1 gram) crystals

Adverse effects

Short-term

Acute adverse effects are usually the result of high or multiple doses, although single dose toxicity can occur in susceptible individuals.[21] The most serious short-term physical health risks of MDMA are hyperthermia and dehydration.[42][75] Cases of life-threatening or fatal hyponatremia (excessively low sodium concentration in the blood) have developed in MDMA users attempting to prevent dehydration by consuming excessive amounts of water without replenishing electrolytes.[42][75][76]

The immediate adverse effects of MDMA use can include:

Other adverse effects that may occur or persist for up to a week following cessation of moderate MDMA use include:[74][21]

Physiological
Psychological

Administration of MDMA to mice causes DNA damage in their brain,[80] especially when the mice are sleep deprived.[81] Even at the very low doses that are comparable to those self-administered by humans, MDMA causes oxidative stress and both single and double-strand breaks in the DNA of the hippocampus region of the mouse brain.[82]

Long-term

As of 2015, the long-term effects of MDMA on human brain structure and function have not been fully determined.[83] However, there is consistent evidence of structural and functional deficits in MDMA users with high lifetime exposure.[83] These structural or functional changes appear to be dose dependent and may be less prominent in MDMA users with only a moderate (typically <50 doses used and <100 tablets consumed) lifetime exposure. Nonetheless, moderate MDMA use may still be neurotoxic and what constitutes moderate use is not clearly established.[84]

Furthermore, it is not clear yet whether "typical" recreational users of MDMA (1 to 2 pills of 75 to 125 mg MDMA or analogue every 1 to 4 weeks) will develop neurotoxic brain lesions.[85] Long-term exposure to MDMA in humans has been shown to produce marked neurodegeneration in striatal, hippocampal, prefrontal, and occipital serotonergic axon terminals.[83][86] Neurotoxic damage to serotonergic axon terminals has been shown to persist for more than two years.[86] Elevations in brain temperature from MDMA use are positively correlated with MDMA-induced neurotoxicity.[15][83][84] However, most studies on MDMA and serotonergic neurotoxicity in humans focus more on heavy users who consume as much as seven times or more the amount that most users report taking. The evidence for the presence of serotonergic neurotoxicity in casual users who take lower doses less frequently is not conclusive.[87]

However, adverse neuroplastic changes to brain microvasculature and white matter have been observed to occur in humans using low doses of MDMA.[15][83] Reduced gray matter density in certain brain structures has also been noted in human MDMA users.[15][83] Global reductions in gray matter volume, thinning of the parietal and orbitofrontal cortices, and decreased hippocampal activity have been observed in long term users.[8] The effects established so far for recreational use of ecstasy lie in the range of moderate to severe effects for serotonin transporter reduction.[88]

Impairments in multiple aspects of cognition, including attention, learning, memory, visual processing, and sleep, have been found in regular MDMA users.[8][21][89][83] The magnitude of these impairments is correlated with lifetime MDMA usage[21][89][83] and are partially reversible with abstinence.[8] Several forms of memory are impaired by chronic ecstasy use;[21][89] however, the effects for memory impairments in ecstasy users are generally small overall.[90][91] MDMA use is also associated with increased impulsivity and depression.[8]

Serotonin depletion following MDMA use can cause depression in subsequent days. In some cases, depressive symptoms persist for longer periods.[8] Some studies indicate repeated recreational use of ecstasy is associated with depression and anxiety, even after quitting the drug.[92] Depression is one of the main reasons for cessation of use.[8]

At high doses, MDMA induces a neuroimmune response that, through several mechanisms, increases the permeability of the blood–brain barrier, thereby making the brain more susceptible to environmental toxins and pathogens.[93][94][page needed] In addition, MDMA has immunosuppressive effects in the peripheral nervous system and pro-inflammatory effects in the central nervous system.[95]

MDMA may increase the risk of cardiac valvulopathy in heavy or long-term users due to activation of serotonin 5-HT2B receptors.[96][97] MDMA induces cardiac epigenetic changes in DNA methylation, particularly hypermethylation changes.[98]

Reinforcement disorders

Approximately 60% of MDMA users experience withdrawal symptoms when they stop taking MDMA.[74] Some of these symptoms include fatigue, loss of appetite, depression, and trouble concentrating.[74] Tolerance to some of the desired and adverse effects of MDMA is expected to occur with consistent MDMA use.[74] A 2007 delphic analysis of a panel of experts in pharmacology, psychiatry, law, policing and others estimated MDMA to have a psychological dependence and physical dependence potential roughly three-fourths to four-fifths that of cannabis.[99]

MDMA has been shown to induce ΔFosB in the nucleus accumbens.[100] Because MDMA releases dopamine in the striatum, the mechanisms by which it induces ΔFosB in the nucleus accumbens are analogous to other dopaminergic psychostimulants.[100][101] Therefore, chronic use of MDMA at high doses can result in altered brain structure and drug addiction that occur as a consequence of ΔFosB overexpression in the nucleus accumbens.[101] MDMA is less addictive than other stimulants such as methamphetamine and cocaine.[102][103] Compared with amphetamine, MDMA and its metabolite MDA are less reinforcing.[104]

One study found approximately 15% of chronic MDMA users met the DSM-IV diagnostic criteria for substance dependence.[105] However, there is little evidence for a specific diagnosable MDMA dependence syndrome because MDMA is typically used relatively infrequently.[51]

There are currently no medications to treat MDMA addiction.[106]

During pregnancy

MDMA is a moderately teratogenic drug (i.e., it is toxic to the fetus).[107][108] In utero exposure to MDMA is associated with a neuro- and cardiotoxicity[108] and impaired motor functioning. Motor delays may be temporary during infancy or long-term. The severity of these developmental delays increases with heavier MDMA use.[89][109] MDMA has been shown to promote the survival of fetal dopaminergic neurons in culture.[110]

Overdose

MDMA overdose symptoms vary widely due to the involvement of multiple organ systems. Some of the more overt overdose symptoms are listed in the table below. The number of instances of fatal MDMA intoxication is low relative to its usage rates. In most fatalities, MDMA was not the only drug involved. Acute toxicity is mainly caused by serotonin syndrome and sympathomimetic effects.[105] Sympathomimetic side effects can be managed with carvedilol.[111][112] MDMA's toxicity in overdose may be exacerbated by caffeine, with which it is frequently cut in order to increase volume.[113] A scheme for management of acute MDMA toxicity has been published focusing on treatment of hyperthermia, hyponatraemia, serotonin syndrome, and multiple organ failure.[114]

Symptoms of overdose
System Minor or moderate overdose[115] Severe overdose[115]
Cardiovascular
Central nervous
system
Musculoskeletal
Respiratory
Urinary
Other

Interactions

A number of drug interactions can occur between MDMA and other drugs, including serotonergic drugs.[74][120] MDMA also interacts with drugs which inhibit CYP450 enzymes, like ritonavir (Norvir), particularly CYP2D6 inhibitors.[74] Life-threatening reactions and death have occurred in people who took MDMA while on ritonavir.[121] Bupropion, a strong CYP2D6 inhibitor, has been found to increase MDMA exposure with administration of MDMA.[122][123] Concurrent use of MDMA high dosages with another serotonergic drug can result in a life-threatening condition called serotonin syndrome.[8][74] Severe overdose resulting in death has also been reported in people who took MDMA in combination with certain monoamine oxidase inhibitors (MAOIs),[8][74] such as phenelzine (Nardil), tranylcypromine (Parnate), or moclobemide (Aurorix, Manerix).[124] Serotonin reuptake inhibitors (SRIs) such as citalopram (Celexa), duloxetine (Cymbalta), fluoxetine (Prozac), and paroxetine (Paxil) have been shown to block most of the subjective effects of MDMA.[125] Norepinephrine reuptake inhibitors (NRIs) such as reboxetine (Edronax) have been found to reduce emotional excitation and feelings of stimulation with MDMA but do not appear to influence its entactogenic or mood-elevating effects.[125]

MDMA induces the release of monoamine neurotransmitters and thereby acts as an indirectly acting sympathomimetic and produces a variety of cardiostimulant effects.[122] It dose-dependently increases heart rate, blood pressure, and cardiac output.[122][126] SRIs like citalopram and paroxetine, as well as the serotonin 5-HT2A receptor antagonist ketanserin, have been found to partially block the increases in heart rate and blood pressure with MDMA.[122][127] It is notable in this regard that serotonergic psychedelics such as psilocybin, which act as serotonin 5-HT2A receptor agonists, likewise have sympathomimetic effects.[128][129][130] The NRI reboxetine and the serotonin–norepinephrine reuptake inhibitor (SNRI) duloxetine block MDMA-induced increases in heart rate and blood pressure.[122] Conversely, bupropion, a norepinephrine–dopamine reuptake inhibitor (NDRI) with only weak dopaminergic activity,[131][132] reduced MDMA-induced heart rate and circulating norepinephrine increases but did not affect MDMA-induced blood pressure increases.[122][123] On the other hand, the robust NDRI methylphenidate, which has sympathomimetic effects of its own, has been found to augment the cardiovascular effects and increases in circulating norepinephrine and epinephrine levels induced by MDMA.[122][133]

The non-selective beta blocker pindolol blocked MDMA-induced increases in heart rate but not blood pressure.[122][111][134] The α2-adrenergic receptor agonist clonidine did not affect the cardiovascular effects of MDMA, though it reduced blood pressure.[122][111][135] The α1-adrenergic receptor antagonists doxazosin and prazosin blocked or reduced MDMA-induced blood pressure increases but augmented MDMA-induced heart rate and cardiac output increases.[122][111][136][126] The dual α1- and β-adrenergic receptor blocker carvedilol reduced MDMA-induced heart rate and blood pressure increases.[122][111][112] In contrast to the cases of serotonergic and noradrenergic agents, the dopamine D2 receptor antagonist haloperidol did not affect the cardiovascular responses to MDMA.[122][137] Due to the theoretical risk of "unopposed α-stimulation" and possible consequences like coronary vasospasm, it has been suggested that dual α1- and β-adrenergic receptor antagonists like carvedilol and labetalol, rather than selective beta blockers, should be used in the management of stimulant-induced sympathomimetic toxicity, for instance in the context of overdose.[111][138]

Pharmacology

Pharmacodynamics

See also: Amphetamine § Pharmacodynamics
Activities of MDMA[17]
Target Affinity (Ki, nM)
SERTTooltip Serotonin transporter 0.73–13,300 (Ki)
380–2,500 (IC50Tooltip half-maximal inhibitory concentration)
50–72 (EC50Tooltip Half-maximal effective concentration) (rat)
NETTooltip Norepinephrine transporter 27,000–30,500 (Ki)
360–405 (IC50)
54–110 (EC50) (rat)
DATTooltip Dopamine transporter 6,500–>10,000 (Ki)
1,440–21,000 (IC50)
51–278 (EC50) (rat)
5-HT1A 6,300–12,200
5-HT1B >10,000
5-HT1D >10,000
5-HT1E >10,000
5-HT1F ND
5-HT2A 4,600–>10,000 (Ki)
6,100–12,484 (EC50)
55% (EmaxTooltip maximal efficacy)
5-HT2B 500–2,000 (Ki)
2,000–>20,000 (EC50)
32% (Emax)
5-HT2C 4,400–>13,000 (Ki)
831–4,299 (EC50)
5-HT3 >10,000
5-HT4 ND
5-HT5A >10,000
5-HT6 >10,000
5-HT7 >10,000
α1A 6,900–>10,000
α1B >10,000
α1D ND
α2A 2,532–15,000
α2B 1,785
α2C 1,123–1,346
β1, β2 >10,000
D1 >13,600
D2 25,200
D3 >17,700
D4 >10,000
D5 >10,000
H1 2,138–>14,400
H2 >10,000
H3, H4 ND
M1 >10,000
M2 >10,000
M3 1,850–>10,000
M4 8,250–>10,000
M5 6,340–>10,000
nACh >10,000
TAAR1 250–370 (Ki) (rat)
1,000–1,700 (EC50) (rat)
2,400–3,100 (Ki) (mouse)
4,000 (EC50) (mouse)
35,000 (EC50) (human)
26% (Emax) (human)
I1 220
σ1, σ2 ND
Notes: The smaller the value, the more avidly the drug binds to the site. Proteins are human unless otherwise specified. Refs: [139][140][17][141][142]
[143][144][145][146][147]

MDMA is a substituted amphetamine structurally, and a monoamine-releasing agent mechanistically. Like other monoamine-releasing agents, MDMA enters monoaminergic neurons through monoamine transporters. MDMA has high affinity for dopamine, norepinephrine and serotonin transporters, with some preference for the latter. The methylenedioxy- substitution provides the serotonergic activity, as most other substituted amphetamines show negligible affinity for the serotonin transporter.[citation needed]

Neurotransmitter release induced by monoamine-releasing agents differs significantly from the regular, action potential-evoked neurotransmitter release. Inside the neuron, MDMA inhibits VMAT2 and activates TAAR1. TAAR1 agonism results in the phosphorylation of monoamine transporters by PKA and PKC, which either internalizes the transporter, or reverses its flux direction.[148][149] VMAT2 inhibition prevents the packaging of the cytosolic monoamines into the synaptic vesicles, which allows them to instead be pumped out of the neuron by the phosphorylated transporters. The result is that the neuron constantly "leaks" neurotransmitters into the synapse, regardless of any signal received.[150]

MDMA has two enantiomers, (S)-MDMA and (R)-MDMA.[16] Recreationally used MDMA is the equimolar mixture of both. (S)-MDMA causes the entactogenic effects of the racemate, because it releases serotonin, norepinephrine and dopamine much more efficiently via monoamine transporters. It also has higher affinity towards 5-HT2CR. (R)-MDMA has notable agonism towards 5-HT2AR,[151] which supposedly contributes to the mild psychedelic hallucinations induced by high doses of MDMA in humans.[152] However, findings on MDMA and the head-twitch response, a behavioral proxy of psychedelic-like effects, are conflicting in animals.[153][154]

Activities of MDMA, its enantiomers, and related compounds
Compound Monoamine release (EC50Tooltip half-maximal effective concentration, nM)
Serotonin Norepinephrine Dopamine
Amphetamine ND ND ND
  (S)-Amphetamine (d) 698–1765 6.6–7.2 5.8–24.8
  (R)-Amphetamine (l) ND 9.5 27.7
Methamphetamine ND ND ND
  (S)-Methamphetamine (d) 736–1291.7 12.3–13.8 8.5–24.5
  (R)-Methamphetamine (l) 4640 28.5 416
MDA 160 108 190
MDMA 49.6–72 54.1–110 51.2–278
  (S)-MDMA (d) 74 136 142
  (R)-MDMA (l) 340 560 3700
MDEA 47 2608 622
MBDB 540 3300 >100000
MDAI 114 117 1334
Notes: The smaller the value, the more strongly the compound produces the effect. Refs: [155][156][157][158][159][160][161][162][17]

Pharmacokinetics

Main metabolic pathways of MDMA in humans.

The MDMA concentration in the blood stream starts to rise after about 30 minutes,[163] and reaches its maximal concentration in the blood stream between 1.5 and 3 hours after ingestion.[164] It is then slowly metabolized and excreted, with levels of MDMA and its metabolites decreasing to half their peak concentration over the next several hours.[165] The duration of action of MDMA is usually four to six hours, after which serotonin levels in the brain are depleted.[8] Serotonin levels typically return to normal within 24–48 hours.[8]

Metabolites of MDMA that have been identified in humans include 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 4-hydroxy-3-methoxyamphetamine (HMA), 3,4-dihydroxyamphetamine (DHA) (also called alpha-methyldopamine (α-Me-DA)), 3,4-methylenedioxyphenylacetone (MDP2P), and 3,4-methylenedioxy-N-hydroxyamphetamine (MDOH). The contributions of these metabolites to the psychoactive and toxic effects of MDMA are an area of active research. 80% of MDMA is metabolised in the liver, and about 20% is excreted unchanged in the urine.[15]

MDMA is known to be metabolized by two main metabolic pathways: (1) O-demethylenation followed by catechol-O-methyltransferase (COMT)-catalyzed methylation and/or glucuronide/sulfate conjugation; and (2) N-dealkylation, deamination, and oxidation to the corresponding benzoic acid derivatives conjugated with glycine.[115] The metabolism may be primarily by cytochrome P450 (CYP450) enzymes CYP2D6 and CYP3A4 and COMT. Complex, nonlinear pharmacokinetics arise via autoinhibition of CYP2D6 and CYP2D8, resulting in zeroth order kinetics at higher doses. It is thought that this can result in sustained and higher concentrations of MDMA if the user takes consecutive doses of the drug.[166][non-primary source needed]

MDMA and metabolites are primarily excreted as conjugates, such as sulfates and glucuronides.[167] MDMA is a chiral compound and has been almost exclusively administered as a racemate. However, the two enantiomers have been shown to exhibit different kinetics. The disposition of MDMA may also be stereoselective, with the S-enantiomer having a shorter elimination half-life and greater excretion than the R-enantiomer. Evidence suggests[168] that the area under the blood plasma concentration versus time curve (AUC) was two to four times higher for the (R)-enantiomer than the (S)-enantiomer after a 40 mg oral dose in human volunteers. Likewise, the plasma half-life of (R)-MDMA was significantly longer than that of the (S)-enantiomer (5.8 ± 2.2 hours vs 3.6 ± 0.9 hours).[74] However, because MDMA excretion and metabolism have nonlinear kinetics,[169] the half-lives would be higher at more typical doses (100 mg is sometimes considered a typical dose).[164]

Chemistry

Racemic MDMA structure diagram
(R)-MDMA
(S)-MDMA
MDMA is a racemic mixture and exists as two enantiomers: (R)-MDMA and (S)-MDMA.
A powdered salt of MDMA
A powdered salt of MDMA
Reactors used in synthesis
Reactors used to synthesize MDMA on an industrial scale in a clandestine chemical factory in Cikande, Indonesia

MDMA is in the substituted methylenedioxyphenethylamine and substituted amphetamine classes of chemicals. As a free base, MDMA is a colorless oil insoluble in water.[10] The most common salt of MDMA is the hydrochloride salt;[10] pure MDMA hydrochloride is water-soluble and appears as a white or off-white powder or crystal.[10]

Synthesis

There are numerous methods available to synthesize MDMA via different intermediates.[170][171][172][173] The original MDMA synthesis described in Merck's patent involves brominating safrole to 1-(3,4-methylenedioxyphenyl)-2-bromopropane and then reacting this adduct with methylamine.[174][175] Most illicit MDMA is synthesized using MDP2P (3,4-methylenedioxyphenyl-2-propanone) as a precursor. MDP2P in turn is generally synthesized from piperonal, safrole or isosafrole.[176] One method is to isomerize safrole to isosafrole in the presence of a strong base, and then oxidize isosafrole to MDP2P. Another method uses the Wacker process to oxidize safrole directly to the MDP2P intermediate with a palladium catalyst. Once the MDP2P intermediate has been prepared, a reductive amination leads to racemic MDMA (an equal parts mixture of (R)-MDMA and (S)-MDMA).[citation needed] Relatively small quantities of essential oil are required to make large amounts of MDMA. The essential oil of Ocotea cymbarum, for example, typically contains between 80 and 94% safrole. This allows 500 mL of the oil to produce between 150 and 340 grams of MDMA.[177]

Synthesis of MDMA from piperonal
Synthesis of MDMA from piperonal
Synthesis of MDMA from piperonal
Synthesis of MDMA and related analogs from safrole
Synthesis of MDMA and related analogs from safrole

Detection in body fluids

MDMA and MDA may be quantitated in blood, plasma or urine to monitor for use, confirm a diagnosis of poisoning or assist in the forensic investigation of a traffic or other criminal violation or a sudden death. Some drug abuse screening programs rely on hair, saliva, or sweat as specimens. Most commercial amphetamine immunoassay screening tests cross-react significantly with MDMA or its major metabolites, but chromatographic techniques can easily distinguish and separately measure each of these substances. The concentrations of MDA in the blood or urine of a person who has taken only MDMA are, in general, less than 10% those of the parent drug.[166][178][179]

History

Early research and use

Merck MDMA synthesis patent
Merck patent for synthesizing methylhydrastinine from MDMA
German patents for MDMA synthesis and the subsequent methylhydrastinine synthesis filed by Merck on 24 December 1912 and issued in 1914

MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch. At the time, Merck was interested in developing substances that stopped abnormal bleeding. Merck wanted to avoid an existing patent held by Bayer for one such compound: hydrastinine. Köllisch developed a preparation of a hydrastinine analogue, methylhydrastinine, at the request of fellow lab members, Walther Beckh and Otto Wolfes. MDMA (called methylsafrylamin, safrylmethylamin or N-Methyl-a-Methylhomopiperonylamin in Merck laboratory reports) was an intermediate compound in the synthesis of methylhydrastinine. Merck was not interested in MDMA itself at the time.[180] On 24 December 1912, Merck filed two patent applications that described the synthesis and some chemical properties of MDMA[181] and its subsequent conversion to methylhydrastinine.[182]

Merck records indicate its researchers returned to the compound sporadically. A 1920 Merck patent describes a chemical modification to MDMA.[183] In 1927, Max Oberlin studied the pharmacology of MDMA while searching for substances with effects similar to adrenaline or ephedrine, the latter being structurally similar to MDMA. Compared to ephedrine, Oberlin observed that it had similar effects on vascular smooth muscle tissue, stronger effects at the uterus, and no "local effect at the eye". MDMA was also found to have effects on blood sugar levels comparable to high doses of ephedrine. Oberlin concluded that the effects of MDMA were not limited to the sympathetic nervous system. Research was stopped "particularly due to a strong price increase of safrylmethylamine", which was still used as an intermediate in methylhydrastinine synthesis. Albert van Schoor performed simple toxicological tests with the drug in 1952, most likely while researching new stimulants or circulatory medications. After pharmacological studies, research on MDMA was not continued. In 1959, Wolfgang Fruhstorfer synthesized MDMA for pharmacological testing while researching stimulants. It is unclear if Fruhstorfer investigated the effects of MDMA in humans.[180]

Outside of Merck, other researchers began to investigate MDMA. In 1953 and 1954, the United States Army commissioned a study of toxicity and behavioral effects in animals injected with mescaline and several analogues, including MDMA. Conducted at the University of Michigan in Ann Arbor, these investigations were declassified in October 1969 and published in 1973.[184][185] A 1960 Polish paper by Biniecki and Krajewski describing the synthesis of MDMA as an intermediate was the first published scientific paper on the substance.[180][185][186]

MDMA may have been in non-medical use in the western United States in 1968.[187] An August 1970 report at a meeting of crime laboratory chemists indicates MDMA was being used recreationally in the Chicago area by 1970.[185][188] MDMA likely emerged as a substitute for its analog 3,4-methylenedioxyamphetamine (MDA),[189] a drug at the time popular among users of psychedelics[190] which was made a Schedule 1 controlled substance in the United States in 1970.[191][192]

Shulgin's research

Alexander and Ann Shulgin in December 2011

American chemist and psychopharmacologist Alexander Shulgin reported he synthesized MDMA in 1965 while researching methylenedioxy compounds at Dow Chemical Company, but did not test the psychoactivity of the compound at this time. Around 1970, Shulgin sent instructions for N-methylated MDA (MDMA) synthesis to the founder of a Los Angeles chemical company who had requested them. This individual later provided these instructions to a client in the Midwest. Shulgin may have suspected he played a role in the emergence of MDMA in Chicago.[185]

Shulgin first heard of the psychoactive effects of N-methylated MDA around 1975 from a young student who reported "amphetamine-like content".[185] Around 30 May 1976, Shulgin again heard about the effects of N-methylated MDA,[185] this time from a graduate student in a medicinal chemistry group he advised at San Francisco State University[190][193] who directed him to the University of Michigan study.[194] She and two close friends had consumed 100 mg of MDMA and reported positive emotional experiences.[185] Following the self-trials of a colleague at the University of San Francisco, Shulgin synthesized MDMA and tried it himself in September and October 1976.[185][190] Shulgin first reported on MDMA in a presentation at a conference in Bethesda, Maryland in December 1976.[185] In 1978, he and David E. Nichols published a report on the drug's psychoactive effect in humans. They described MDMA as inducing "an easily controlled altered state of consciousness with emotional and sensual overtones" comparable "to marijuana, to psilocybin devoid of the hallucinatory component, or to low levels of MDA".[195]

While not finding his own experiences with MDMA particularly powerful,[194][196] Shulgin was impressed with the drug's disinhibiting effects and thought it could be useful in therapy.[196] Believing MDMA allowed users to strip away habits and perceive the world clearly, Shulgin called the drug window.[194][197] Shulgin occasionally used MDMA for relaxation, referring to it as "my low-calorie martini", and gave the drug to friends, researchers, and others who he thought could benefit from it.[194] One such person was Leo Zeff, a psychotherapist who had been known to use psychedelic substances in his practice. When he tried the drug in 1977, Zeff was impressed with the effects of MDMA and came out of his semi-retirement to promote its use in therapy. Over the following years, Zeff traveled around the United States and occasionally to Europe, eventually training an estimated four thousand psychotherapists in the therapeutic use of MDMA.[196][198] Zeff named the drug Adam, believing it put users in a state of primordial innocence.[190]

Psychotherapists who used MDMA believed the drug eliminated the typical fear response and increased communication. Sessions were usually held in the home of the patient or the therapist. The role of the therapist was minimized in favor of patient self-discovery accompanied by MDMA induced feelings of empathy. Depression, substance use disorders, relationship problems, premenstrual syndrome, and autism were among several psychiatric disorders MDMA assisted therapy was reported to treat.[192] According to psychiatrist George Greer, therapists who used MDMA in their practice were impressed by the results. Anecdotally, MDMA was said to greatly accelerate therapy.[196] According to David Nutt, MDMA was widely used in the western US in couples counseling, and was called empathy. Only later was the term ecstasy used for it, coinciding with rising opposition to its use.[199][200]

Rising recreational use

In the late 1970s and early 1980s, "Adam" spread through personal networks of psychotherapists, psychiatrists, users of psychedelics, and yuppies. Hoping MDMA could avoid criminalization like LSD and mescaline, psychotherapists and experimenters attempted to limit the spread of MDMA and information about it while conducting informal research.[192][201] Early MDMA distributors were deterred from large scale operations by the threat of possible legislation.[202] Between the 1970s and the mid-1980s, this network of MDMA users consumed an estimated 500,000 doses.[21][203]

A small recreational market for MDMA developed by the late 1970s,[204] consuming perhaps 10,000 doses in 1976.[191] By the early 1980s MDMA was being used in Boston and New York City nightclubs such as Studio 54 and Paradise Garage.[205][206] Into the early 1980s, as the recreational market slowly expanded, production of MDMA was dominated by a small group of therapeutically minded Boston chemists. Having commenced production in 1976, this "Boston Group" did not keep up with growing demand and shortages frequently occurred.[202]

Perceiving a business opportunity, Michael Clegg, the Southwest distributor for the Boston Group, started his own "Texas Group" backed financially by Texas friends.[202][207] In 1981,[202] Clegg had coined "Ecstasy" as a slang term for MDMA to increase its marketability.[197][201] Starting in 1983,[202] the Texas Group mass-produced MDMA in a Texas lab[201] or imported it from California[197] and marketed tablets using pyramid sales structures and toll-free numbers.[203] MDMA could be purchased via credit card and taxes were paid on sales.[202] Under the brand name "Sassyfras", MDMA tablets were sold in brown bottles.[201] The Texas Group advertised "Ecstasy parties" at bars and discos, describing MDMA as a "fun drug" and "good to dance to".[202] MDMA was openly distributed in Austin and Dallas–Fort Worth area bars and nightclubs, becoming popular with yuppies, college students, and gays.[189][202][203]

Recreational use also increased after several cocaine dealers switched to distributing MDMA following experiences with the drug.[203] A California laboratory that analyzed confidentially submitted drug samples first detected MDMA in 1975. Over the following years the number of MDMA samples increased, eventually exceeding the number of MDA samples in the early 1980s.[208][209] By the mid-1980s, MDMA use had spread to colleges around the United States.[202]: 33 

Media attention and scheduling

United States

27 July 1984 Federal Register notice of the proposed MDMA scheduling

In an early media report on MDMA published in 1982, a Drug Enforcement Administration (DEA) spokesman stated the agency would ban the drug if enough evidence for abuse could be found.[202] By mid-1984, MDMA use was becoming more noticed. Bill Mandel reported on "Adam" in a 10 June San Francisco Chronicle article, but misidentified the drug as methyloxymethylenedioxyamphetamine (MMDA). In the next month, the World Health Organization identified MDMA as the only substance out of twenty phenethylamines to be seized a significant number of times.[201]

After a year of planning and data collection, MDMA was proposed for scheduling by the DEA on 27 July 1984 with a request for comments and objections.[201][210] The DEA was surprised when a number of psychiatrists, psychotherapists, and researchers objected to the proposed scheduling and requested a hearing.[192] In a Newsweek article published the next year, a DEA pharmacologist stated that the agency had been unaware of its use among psychiatrists.[211] An initial hearing was held on 1 February 1985 at the DEA offices in Washington, D.C., with administrative law judge Francis L. Young presiding.[201] It was decided there to hold three more hearings that year: Los Angeles on 10 June, Kansas City, Missouri on 10–11 July, and Washington, D.C., on 8–11 October.[192][201]

Sensational media attention was given to the proposed criminalization and the reaction of MDMA proponents, effectively advertising the drug.[192] In response to the proposed scheduling, the Texas Group increased production from 1985 estimates of 30,000 tablets a month to as many as 8,000 per day, potentially making two million ecstasy tablets in the months before MDMA was made illegal.[212] By some estimates the Texas Group distributed 500,000 tablets per month in Dallas alone.[197] According to one participant in an ethnographic study, the Texas Group produced more MDMA in eighteen months than all other distribution networks combined across their entire histories.[202] By May 1985, MDMA use was widespread in California, Texas, southern Florida, and the northeastern United States.[187][213] According to the DEA there was evidence of use in twenty-eight states[214] and Canada.[187] Urged by Senator Lloyd Bentsen, the DEA announced an emergency Schedule I classification of MDMA on 31 May 1985. The agency cited increased distribution in Texas, escalating street use, and new evidence of MDA (an analog of MDMA) neurotoxicity as reasons for the emergency measure.[213][215][216] The ban took effect one month later on 1 July 1985[212] in the midst of Nancy Reagan's "Just Say No" campaign.[217][218]

As a result of several expert witnesses testifying that MDMA had an accepted medical usage, the administrative law judge presiding over the hearings recommended that MDMA be classified as a Schedule III substance. Despite this, DEA administrator John C. Lawn overruled and classified the drug as Schedule I.[192][219] Harvard psychiatrist Lester Grinspoon then sued the DEA, claiming that the DEA had ignored the medical uses of MDMA, and the federal court sided with Grinspoon, calling Lawn's argument "strained" and "unpersuasive", and vacated MDMA's Schedule I status.[220] Despite this, less than a month later Lawn reviewed the evidence and reclassified MDMA as Schedule I again, claiming that the expert testimony of several psychiatrists claiming over 200 cases where MDMA had been used in a therapeutic context with positive results could be dismissed because they were not published in medical journals.[192] In 2017, the FDA granted breakthrough therapy designation for its use with psychotherapy for PTSD. However, this designation has been questioned and problematized.[221]

United Nations

While engaged in scheduling debates in the United States, the DEA also pushed for international scheduling.[212] In 1985 the World Health Organization's Expert Committee on Drug Dependence recommended that MDMA be placed in Schedule I of the 1971 United Nations Convention on Psychotropic Substances. The committee made this recommendation on the basis of the pharmacological similarity of MDMA to previously scheduled drugs, reports of illicit trafficking in Canada, drug seizures in the United States, and lack of well-defined therapeutic use. While intrigued by reports of psychotherapeutic uses for the drug, the committee viewed the studies as lacking appropriate methodological design and encouraged further research. Committee chairman Paul Grof dissented, believing international control was not warranted at the time and a recommendation should await further therapeutic data.[222] The Commission on Narcotic Drugs added MDMA to Schedule I of the convention on 11 February 1986.[223]

Post-scheduling

A 1995 Vibe Tribe rave in Erskineville, New South Wales, Australia being broken up by police. MDMA use spread globally along with rave culture.
A 2000 United States Air Force video dramatizing the dangers of MDMA misuse

The use of MDMA in Texas clubs declined rapidly after criminalization, although by 1991 the drug remained popular among young middle-class whites and in nightclubs.[202]: 46  In 1985, MDMA use became associated with acid house on the Spanish island of Ibiza.[202]: 50 [224] Thereafter in the late 1980s, the drug spread alongside rave culture to the UK and then to other European and American cities.[202]: 50  Illicit MDMA use became increasingly widespread among young adults in universities and later, in high schools. Since the mid-1990s, MDMA has become the most widely used amphetamine-type drug by college students and teenagers.[225]: 1080  MDMA became one of the four most widely used illicit drugs in the US, along with cocaine, heroin, and cannabis.[197] According to some estimates as of 2004, only marijuana attracts more first time users in the US.[197]

After MDMA was criminalized, most medical use stopped, although some therapists continued to prescribe the drug illegally. Later,[when?] Charles Grob initiated an ascending-dose safety study in healthy volunteers. Subsequent FDA-approved MDMA studies in humans have taken place in the United States in Detroit (Wayne State University), Chicago (University of Chicago), San Francisco (UCSF and California Pacific Medical Center), Baltimore (NIDA–NIH Intramural Program), and South Carolina. Studies have also been conducted in Switzerland (University Hospital of Psychiatry, Zürich), the Netherlands (Maastricht University), and Spain (Universitat Autònoma de Barcelona).[226]

"Molly", short for 'molecule', was recognized as a slang term for crystalline or powder MDMA in the 2000s.[227][228]

In 2010, the BBC reported that use of MDMA had decreased in the UK in previous years. This may be due to increased seizures during use and decreased production of the precursor chemicals used to manufacture MDMA. Unwitting substitution with other drugs, such as mephedrone and methamphetamine,[229] as well as legal alternatives to MDMA, such as BZP, MDPV, and methylone, are also thought to have contributed to its decrease in popularity.[230]

In 2017 it was found that some pills being sold as MDMA contained pentylone, which can cause very unpleasant agitation and paranoia.[231]

According to David Nutt, when safrole was restricted by the United Nations in order to reduce the supply of MDMA, producers in China began using anethole instead, but this gives para-methoxyamphetamine (PMA, also known as "Dr Death"), which is much more toxic than MDMA and can cause overheating, muscle spasms, seizures, unconsciousness, and death. People wanting MDMA are sometimes sold PMA instead.[199]

Society and culture

Global estimates of drug users in 2016
(in millions of users)[232]
Substance Best
estimate		 Low
estimate		 High
estimate
Amphetamine-
type stimulants		 34.16 13.42 55.24
Cannabis 192.15 165.76 234.06
Cocaine 18.20 13.87 22.85
Ecstasy 20.57 8.99 32.34
Opiates 19.38 13.80 26.15
Opioids 34.26 27.01 44.54

MDMA is legally controlled in most of the world under the UN Convention on Psychotropic Substances and other international agreements, although exceptions exist for research and limited medical use. In general, the unlicensed use, sale or manufacture of MDMA are all criminal offences.

Australia

In Australia, MDMA was rescheduled on 1 July 2023 as a schedule 8 substance (available on prescription) when used in the treatment of PTSD, while remaining a schedule 9 substance (prohibited) for all other uses. For the treatment of PTSD, MDMA can only be prescribed by psychiatrists with specific training and authorisation.[233] In 1986, MDMA was declared an illegal substance because of its allegedly harmful effects and potential for misuse.[234] Any non-authorised sale, use or manufacture is strictly prohibited by law. Permits for research uses on humans must be approved by a recognized ethics committee on human research.

In Western Australia under the Misuse of Drugs Act 1981 4.0g of MDMA is the amount required determining a court of trial, 2.0g is considered a presumption with intent to sell or supply and 28.0g is considered trafficking under Australian law.[235]

The Australian Capital Territory passed legislation to decriminalise the possession of small amounts of MDMA, which took effect in October 2023.[236][237]

United Kingdom

In the United Kingdom, MDMA was made illegal in 1977 by a modification order to the existing Misuse of Drugs Act 1971. Although MDMA was not named explicitly in this legislation, the order extended the definition of Class A drugs to include various ring-substituted phenethylamines.[238][239] The drug is therefore illegal to sell, buy, or possess without a licence in the UK. Penalties include a maximum of seven years and/or unlimited fine for possession; life and/or unlimited fine for production or trafficking.

Some researchers such as David Nutt have criticized the scheduling of MDMA, which he determined to be a relatively harmless drug.[240][241] An editorial he wrote in the Journal of Psychopharmacology, where he compared the risk of harm for horse riding (1 adverse event in 350) to that of ecstasy (1 in 10,000) resulted in his dismissal as well as the resignation of his colleagues from the ACMD.[242]

United States

In the United States, MDMA is listed in Schedule I of the Controlled Substances Act.[243] In a 2011 federal court hearing, the American Civil Liberties Union successfully argued that the sentencing guideline for MDMA/ecstasy is based on outdated science, leading to excessive prison sentences.[244] Other courts have upheld the sentencing guidelines. The United States District Court for the Eastern District of Tennessee explained its ruling by noting that "an individual federal district court judge simply cannot marshal resources akin to those available to the Commission for tackling the manifold issues involved with determining a proper drug equivalency."[245]

Netherlands

In the Netherlands, the Expert Committee on the List (Expertcommissie Lijstensystematiek Opiumwet) issued a report in June 2011 which discussed the evidence for harm and the legal status of MDMA, arguing in favor of maintaining it on List I.[245][246][247]

Canada

In Canada, MDMA is listed as a Schedule 1[248] as it is an analogue of amphetamine.[249] The Controlled Drugs and Substances Act was updated as a result of the Safe Streets and Communities Act changing amphetamines from Schedule III to Schedule I in March 2012. In 2022, the federal government granted British Columbia a 3-year exemption, legalizing the possession of up to 2.5 grams (0.088 oz) of MDMA in the province from February 2023 until February 2026.[250][251]

Demographics

UNODC map showing the use of ecstasy by country in 2014 for the global population aged 15–64

In 2014, 3.5% of 18 to 25 year-olds had used MDMA in the United States.[8] In the European Union as of 2018, 4.1% of adults (15–64 years old) have used MDMA at least once in their life, and 0.8% had used it in the last year.[252] Among young adults, 1.8% had used MDMA in the last year.[252]

In Europe, an estimated 37% of regular club-goers aged 14 to 35 used MDMA in the past year according to the 2015 European Drug report.[8] The highest one-year prevalence of MDMA use in Germany in 2012 was 1.7% among people aged 25 to 29 compared with a population average of 0.4%.[8] Among adolescent users in the United States between 1999 and 2008, girls were more likely to use MDMA than boys.[253]

Economics

Europe

In 2008 the European Monitoring Centre for Drugs and Drug Addiction noted that although there were some reports of tablets being sold for as little as €1, most countries in Europe then reported typical retail prices in the range of €3 to €9 per tablet, typically containing 25–65 mg of MDMA.[254] By 2014 the EMCDDA reported that the range was more usually between €5 and €10 per tablet, typically containing 57–102 mg of MDMA, although MDMA in powder form was becoming more common.[255]

North America

The United Nations Office on Drugs and Crime stated in its 2014 World Drug Report that US ecstasy retail prices range from US$1 to $70 per pill, or from $15,000 to $32,000 per kilogram.[256] A new research area named Drug Intelligence aims to automatically monitor distribution networks based on image processing and machine learning techniques, in which an Ecstasy pill picture is analyzed to detect correlations among different production batches.[257] These novel techniques allow police scientists to facilitate the monitoring of illicit distribution networks.

As of October 2015, most of the MDMA in the United States is produced in British Columbia, Canada and imported by Canada-based Asian transnational criminal organizations.[69] The market for MDMA in the United States is relatively small compared to methamphetamine, cocaine, and heroin.[69] In the United States, about 0.9 million people used ecstasy in 2010.[25]

Australia

MDMA is particularly expensive in Australia, costing A$15–A$30 per tablet. In terms of purity data for Australian MDMA, the average is around 34%, ranging from less than 1% to about 85%. The majority of tablets contain 70–85 mg of MDMA. Most MDMA enters Australia from the Netherlands, the UK, Asia, and the US.[258]

Corporate logos on pills

A number of ecstasy manufacturers brand their pills with a logo, often being the logo of an unrelated corporation.[259] Some pills depict logos of products or media popular with children, such as Shaun the Sheep.[260]

Research directions

See also: List of investigational anxiolytics and Psychedelic therapy

A 2014 review of the safety and efficacy of MDMA as a treatment for various disorders, particularly post-traumatic stress disorder (PTSD), indicated that MDMA has therapeutic efficacy in some patients.[89] Four clinical trials provide moderate evidence in support of this treatment.[261] Some authors have concluded that because of MDMA's potential to cause lasting harm in humans (e.g., serotonergic neurotoxicity and persistent memory impairment), "considerably more research must be performed" on its efficacy in PTSD treatment to determine if the potential treatment benefits outweigh its potential to harm a patient.[21][89] Other authors have argued that the neurotoxic effects of MDMA are dose-dependent,[262] with lower doses exhibiting lower neurotoxicity or even neuroprotection,[263] and that MDMA assisted psychotherapy is considerably safer than current treatments.[264]

Animal models suggest that postnatal exposure may ameliorate social impairments in autism.[265]

Recent evidence suggests the safe and potentially effective use of MDMA to treat the negative symptoms of schizophrenia.[266] Unlike other treatments for mental illness, MDMA would be intended to be used infrequently and alongside psychotherapy in treatment.

References

  1. ^ "FDA Substance Registration System". United States National Library of Medicine. Archived from the original on 31 August 2017. Retrieved 31 August 2017.
  2. ^ a b Luciano RL, Perazella MA (June 2014). "Nephrotoxic effects of designer drugs: synthetic is not better!". Nature Reviews. Nephrology. 10 (6): 314–24. doi:10.1038/nrneph.2014.44. ISSN 1759-5061. PMID 24662435. S2CID 9817771.
  3. ^ a b c "DrugFacts: MDMA (Ecstasy or Molly)". National Institute on Drug Abuse. Archived from the original on 3 December 2014. Retrieved 2 December 2014.
  4. ^ "Pingers, pingas, pingaz: how drug slang affects the way we use and understand drugs". The Conversation. 8 January 2020. Archived from the original on 15 January 2021.
  5. ^ Palmer RB (2012). Medical toxicology of drug abuse : synthesized chemicals and psychoactive plants. Hoboken, N.J.: John Wiley & Sons. p. 139. ISBN 978-0-471-72760-6. Archived from the original on 13 January 2023. Retrieved 4 September 2017.
  6. ^ Upfal J (2022). Australian Drug Guide: The Plain Language Guide to Drugs and Medicines of All Kinds (9th ed.). Melbourne: Black Inc. p. 319. ISBN 9781760643195. Habit-forming potential moderate. Ecstasy may induce psychological dependence and tolerance to its effect when used frequently.
  7. ^ Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 375. ISBN 978-0-07-148127-4.
  8. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj Betzler F, Viohl L, Romanczuk-Seiferth N (January 2017). "Decision-making in chronic ecstasy users: a systematic review". The European Journal of Neuroscience. 45 (1): 34–44. doi:10.1111/ejn.13480. PMID 27859780. S2CID 31694072. ...the addictive potential of MDMA itself is relatively small.
  9. ^ Jerome L, Schuster S, Yazar-Klosinski BB (March 2013). "Can MDMA play a role in the treatment of substance abuse?" (PDF). Current Drug Abuse Reviews. 6 (1): 54–62. doi:10.2174/18744737112059990005. PMID 23627786. S2CID 9327169. Archived from the original (PDF) on 3 August 2020. Animal and human studies demonstrate moderate abuse liability for MDMA, and this effect may be of most concern to those treating substance abuse disorders.
  10. ^ a b c d e f g h i j k l m n "Methylenedioxymethamphetamine (MDMA or 'Ecstasy')". EMCDDA. European Monitoring Centre for Drugs and Drug Addiction. Archived from the original on 1 January 2016. Retrieved 17 October 2014.
  11. ^ "Methylenedioxymethamphetamine (MDMA, ecstasy)". Drugs and Human Performance Fact Sheets. National Highway Traffic Safety Administration. Archived from the original on 3 May 2012.
  12. ^ Anvisa (24 July 2023). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 25 July 2023). Archived from the original on 27 August 2023. Retrieved 27 August 2023.
  13. ^ a b c d Freye E (28 July 2009). "Pharmacological Effects of MDMA in Man". Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Springer Netherlands. pp. 151–160. doi:10.1007/978-90-481-2448-0_24. ISBN 978-90-481-2448-0.
  14. ^ "Midomafetamine: Uses, Interactions, Mechanism of Action". DrugBank Online. 31 July 2007. Retrieved 11 December 2024.
  15. ^ a b c d e f g h i j k l m n o p Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, et al. (August 2012). "Toxicity of amphetamines: an update". Archives of Toxicology. 86 (8): 1167–231. Bibcode:2012ArTox..86.1167C. doi:10.1007/s00204-012-0815-5. PMID 22392347. S2CID 2873101.
  16. ^ a b c d Straumann I, Avedisian I, Klaiber A, Varghese N, Eckert A, Rudin D, et al. (August 2024). "Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants". Neuropsychopharmacology. 50 (2): 362–371. doi:10.1038/s41386-024-01972-6. PMC 11631982. PMID 39179638.{{cite journal}}: CS1 maint: overridden setting (link)
  17. ^ a b c d e Dunlap LE, Andrews AM, Olson DE (October 2018). "Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine" (PDF). ACS Chem Neurosci. 9 (10): 2408–2427. doi:10.1021/acschemneuro.8b00155. PMC 6197894. PMID 30001118.
  18. ^ Palamar JJ (7 December 2016). "There's something about Molly: The underresearched yet popular powder form of ecstasy in the United States". Substance Abuse. 38 (1): 15–17. doi:10.1080/08897077.2016.1267070. PMC 5578728. PMID 27925866.
  19. ^ Skaug HA, ed. (14 December 2020). "Hva er tryggest av molly og ecstasy?" [What is safer: molly or ecstasy?]. Ung.no (in Norwegian). Norwegian Directorate for Children, Youth and Family Affairs. Archived from the original on 11 August 2022. Retrieved 20 June 2022. MDMA er virkestoffet i både Molly-krystaller og Ecstasy-tabletter. (MDMA is the active substance in both Molly crystals and Ecstasy tablets)
  20. ^ Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (September 2003). "The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")". Pharmacol Rev. 55 (3): 463–508. doi:10.1124/pr.55.3.3. PMID 12869661.
  21. ^ a b c d e f g h i j k l m n o p q r Meyer JS (2013). "3,4-methylenedioxymethamphetamine (MDMA): current perspectives". Substance Abuse and Rehabilitation. 4: 83–99. doi:10.2147/SAR.S37258. PMC 3931692. PMID 24648791.
  22. ^ Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. (July 2023). "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study". Focus. 21 (3): 315–328. doi:10.1176/appi.focus.23021011. PMC 10316215. PMID 37404971.
  23. ^ a b Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS (January 2016). "MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 64: 237–249. doi:10.1016/j.pnpbp.2015.03.011. PMID 25818246.
  24. ^ a b Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, et al. (November 2018). "Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study". Psychopharmacology. 235 (11): 3137–3148. doi:10.1007/s00213-018-5010-9. PMC 6208958. PMID 30196397.
  25. ^ a b c d e f g h Anderson L, ed. (18 May 2014). "MDMA". Drugs.com. Drugsite Trust. Archived from the original on 23 March 2016. Retrieved 30 March 2016.
  26. ^ a b c d "DrugFacts: MDMA (Ecstasy/Molly)". National Institute on Drug Abuse. February 2016. Archived from the original on 23 March 2016. Retrieved 30 March 2016.
  27. ^ Freudenmann RW, Öxler F, Bernschneider-Reif S (August 2006). "The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents" (PDF). Addiction. 101 (9): 1241–1245. doi:10.1111/j.1360-0443.2006.01511.x. PMID 16911722. Archived (PDF) from the original on 22 September 2020. Retrieved 23 May 2019. Although MDMA was, in fact, first synthesized at Merck in 1912, it was not tested pharmacologically because it was only an unimportant precursor in a new synthesis for haemostatic substances.
  28. ^ World Health Organization (2004). Neuroscience of Psychoactive Substance Use and Dependence. World Health Organization. pp. 97–. ISBN 978-92-4-156235-5. Archived from the original on 28 April 2016.
  29. ^ a b World Drug Report 2018 (PDF). United Nations. June 2018. p. 7. ISBN 978-92-1-148304-8. Archived (PDF) from the original on 27 July 2018. Retrieved 14 July 2018.
  30. ^ "MDMA (Ecstasy/Molly)". National Institute on Drug Abuse. Archived from the original on 15 July 2018. Retrieved 14 July 2018.
  31. ^ White CM (March 2014). "How MDMA's pharmacology and pharmacokinetics drive desired effects and harms". Journal of Clinical Pharmacology. 54 (3): 245–252. doi:10.1002/jcph.266. PMID 24431106. S2CID 6223741.
  32. ^ Sessa B, Aday JS, O'Brien S, Curran HV, Measham F, Higbed L, et al. (March 2022). "Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA". Journal of Psychopharmacology. 36 (3): 360–367. doi:10.1177/02698811211055809. PMID 34894842. S2CID 245184699.
  33. ^ Freye E (2009). Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs: A comprehensive review on their mode of action, treatment of abuse and intoxication. Springer Science & Business Media. p. 147. ISBN 978-90-481-2448-0. Archived from the original on 13 January 2023. Retrieved 12 May 2020.
  34. ^ Lyles J, Cadet JL (May 2003). "Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms". Brain Research. Brain Research Reviews. 42 (2): 155–168. doi:10.1016/S0165-0173(03)00173-5. PMID 12738056. S2CID 45330713.
  35. ^ Philipps D (1 May 2018). "Ecstasy as a Remedy for PTSD? You Probably Have Some Questions". The New York Times. Archived from the original on 1 January 2022. Retrieved 14 July 2018.
  36. ^ Patel V (2010). Mental and neurological public health a global perspective (1st ed.). San Diego, CA: Academic Press/Elsevier. p. 57. ISBN 978-0-12-381527-9. Archived from the original on 10 September 2017.
  37. ^ Nuwer R (3 May 2021). "A Psychedelic Drug Passes a Big Test for PTSD Treatment". The New York Times. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
  38. ^ "Subsection 56(1) class exemption for practitioners, agents, pharmacists, persons in charge of a hospital, hospital employees, and licensed dealers to conduct activities with psilocybin and MDMA in relation to a special access program authorization". Health Canada. 5 January 2022. Archived from the original on 11 February 2022. Retrieved 20 February 2022.
  39. ^ "Canada approving psychedelics for therapy is a positive step, experts say - National". Globalnews.ca. Archived from the original on 20 February 2022. Retrieved 20 February 2022.
  40. ^ "Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists". 3 February 2023. Archived from the original on 4 February 2024. Retrieved 4 February 2024.
  41. ^ Liechti ME, Gamma A, Vollenweider FX (March 2001). "Gender differences in the subjective effects of MDMA". Psychopharmacology. 154 (2): 161–8. doi:10.1007/s002130000648. PMID 11314678. S2CID 20251888.
  42. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad Greene SL, Kerr F, Braitberg G (October 2008). "Review article: amphetamines and related drugs of abuse". Emergency Medicine Australasia. 20 (5): 391–402. doi:10.1111/j.1742-6723.2008.01114.x. PMID 18973636. S2CID 20755466.
  43. ^ a b Landriscina F (1995). "MDMA and the states of Consciousness". Eleusis. 2: 3–9.
  44. ^ Baggott MJ, Kirkpatrick MG, Bedi G, de Wit H (June 2015). "Intimate insight: MDMA changes how people talk about significant others". Journal of Psychopharmacology. 29 (6): 669–77. doi:10.1177/0269881115581962. PMC 4698152. PMID 25922420.
  45. ^ a b Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME (September 2014). "Differential effects of MDMA and methylphenidate on social cognition" (PDF). Journal of Psychopharmacology. 28 (9): 847–56. doi:10.1177/0269881114542454. PMID 25052243. S2CID 25713943. Archived (PDF) from the original on 17 September 2020. Retrieved 29 June 2019.
  46. ^ Wardle MC, de Wit H (October 2014). "MDMA alters emotional processing and facilitates positive social interaction". Psychopharmacology. 231 (21): 4219–29. doi:10.1007/s00213-014-3570-x. PMC 4194242. PMID 24728603.
  47. ^ Bravo GL (2001). "What does MDMA feel like?". In Holland J (ed.). Ecstasy: The complete guide. A comprehensive look at the risks and benefits of MDMA. Rochester: Park Street Press.
  48. ^ Metzner R (2005). "Psychedelic, Psychoactive, and Addictive Drugs and States of Consciousness". In Earleywine M (ed.). Mind-Altering Drugs: The Science of Subjective Experience. New York: Oxford University. Archived from the original on 9 October 2017. Retrieved 8 October 2017.
  49. ^ Kamilar-Britt P, Bedi G (October 2015). "The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals". Neuroscience and Biobehavioral Reviews. 57: 433–46. doi:10.1016/j.neubiorev.2015.08.016. PMC 4678620. PMID 26408071.
  50. ^ Reynolds S (1999). Generation Ecstasy: Into the World of Techno and Rave Culture. Routledge. p. 81. ISBN 978-0-415-92373-6. Archived from the original on 8 November 2023. Retrieved 13 October 2020.
  51. ^ a b McCrady BS, Epstein EE, eds. (2013). Addictions: a comprehensive guidebook (Second ed.). Oxford: Oxford University Press. p. 299. ISBN 978-0-19-975366-6. Archived from the original on 13 January 2023. Retrieved 11 January 2017.
  52. ^ a b Zeifman RJ, Kettner H, Pagni BA, Mallard A, Roberts DE, Erritzoe D, et al. (August 2023). "Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences". Scientific Reports. 13 (1): 13645. Bibcode:2023NatSR..1313645Z. doi:10.1038/s41598-023-40856-5. PMC 10444769. PMID 37608057.
  53. ^ Weiss S (16 February 2024). "Nexus Flipping: What Happens When You Combine MDMA and 2C-B". DoubleBlind Mag. Retrieved 10 July 2024.
  54. ^ Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, et al. (4 May 2012). Laks J (ed.). "Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study". PLOS ONE. 7 (5): e36476. Bibcode:2012PLoSO...736476H. doi:10.1371/journal.pone.0036476. PMC 3344887. PMID 22574166.
  55. ^ Yuki F, Rie I, Miki K, Mitsuhiro W, Naotaka K, Kenichiro N (April 2013). "Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain". European Journal of Pharmaceutical Sciences. 49 (1): 57–64. doi:10.1016/j.ejps.2013.01.014. PMID 23395913.
  56. ^ Hamida SB, Tracqui A, de Vasconcelos AP, Szwarc E, Lazarus C, Kelche C, et al. (July 2009). "Ethanol increases the distribution of MDMA to the rat brain: possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA". The International Journal of Neuropsychopharmacology. 12 (6): 749–759. doi:10.1017/s1461145708009693. PMID 19046482. S2CID 24230367.
  57. ^ Oesterheld JR, Armstrong SC, Cozza KL (1 March 2004). "Ecstasy: pharmacodynamic and pharmacokinetic interactions". Psychosomatics. 45 (1): 84–87. doi:10.1176/appi.psy.45.1.84. PMID 14709765.
  58. ^ Carpenter M, Berry H, Pelletier AL (May 2019). "Clinically Relevant Drug-Drug Interactions in Primary Care". American Family Physician. 99 (9): 558–564. PMID 31038898.
  59. ^ Sessa B, Nutt D (January 2015). "Making a medicine out of MDMA". The British Journal of Psychiatry. 206 (1): 4–6. doi:10.1192/bjp.bp.114.152751. PMID 25561485.
  60. ^ Ebrahimian Z, Karimi Z, Khoshnoud MJ, Namavar MR, Daraei B, Haidari MR (1 February 2017). "Behavioral and Stereological Analysis of the Effects of Intermittent Feeding Diet on the Orally Administrated MDMA ("ecstasy") in Mice". Innovations in Clinical Neuroscience. 14 (1–2): 40–52. PMC 5373794. PMID 28386520. MDMA is listed as a Schedule 1 drug by the United States Drug Enforcement Agency, meaning that currently there are no accepted medical uses for MDMA in the United States, there is a lack of accepted safety for use under medical supervision, and there is a high potential for abuse.
  61. ^ Climko RP, Roehrich H, Sweeney DR, Al-Razi J (1986). "Ecstacy: a review of MDMA and MDA". International Journal of Psychiatry in Medicine. 16 (4): 359–72. doi:10.2190/dcrp-u22m-aumd-d84h. PMID 2881902. S2CID 31902958.
  62. ^ Wan W (6 August 2017). "Ecstasy could be 'breakthrough' therapy for soldiers, others suffering from PTSD". The Washington Post. Archived from the original on 28 August 2017. Retrieved 3 April 2021.
  63. ^ Kupferschmidt K (26 August 2017). "All clear for the decisive trial of ecstasy in PTSD patients". Science (magazine). Archived from the original on 28 December 2021. Retrieved 3 April 2021.
  64. ^ Zarembo A (15 March 2014). "Exploring therapeutic effects of MDMA on post-traumatic stress". Los Angeles Times. Archived from the original on 7 April 2023. Retrieved 7 April 2023.
  65. ^ Singleton SP, Wang J, Mithoefer M, Hanlon CA, George MS, Mithoefer A, et al. (2023). "Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder". Frontiers in Psychiatry. 13: 947622. doi:10.3389/fpsyt.2022.947622. ISSN 1664-0640. PMC 9879604. PMID 36713926.
  66. ^ "Psychedelic Support: First Clinical Trial: Social Anxiety in Autistic Adults Successfully Treated with MDMA Therapy – Multidisciplinary Association for Psychedelic Studies – MAPS". maps.org. Retrieved 17 September 2024.
  67. ^ Saunders N (29 July 1995). "The Agony and Ecstasy of God's path". Council on Spiritual Practices (CSP). Archived from the original on 24 April 2013. Retrieved 11 June 2011.
  68. ^ Watson L, Beck J (1991). "New age seekers: MDMA use as an adjunct to spiritual pursuit" (PDF). Journal of Psychoactive Drugs. 23 (3): 261–70. doi:10.1080/02791072.1991.10471587. PMID 1685513. Archived from the original on 22 November 2004. Retrieved 28 April 2024.{{cite journal}}: CS1 maint: bot: original URL status unknown (link)
  69. ^ a b c d "MDMA (3,4-Methylenedioxymethamphetamine)" (PDF). 2015 National Drug Threat Assessment Summary. United States Department of Justice: Drug Enforcement Administration. October 2015. pp. 85–88. Archived from the original (PDF) on 10 April 2016. Retrieved 10 April 2016.
  70. ^ a b Molly Madness. Drugs, Inc. (TV documentary). National Geographic Channel. 13 August 2014. ASIN B00LIC368M.
  71. ^ a b Manic Molly. Drugs, Inc. (TV documentary). National Geographic Channel. 10 December 2014. ASIN B00LIC368M.
  72. ^ Kelly M (20 June 2019). "Man arrested for possession of ecstasy tablets shaped like Wario". Nintendo Enthusiast. Archived from the original on 24 June 2021. Retrieved 17 June 2021.
  73. ^ "Groesbeck: Students caught with deceptively shaped Ecstasy pills". KWTX. 31 October 2019. Archived from the original on 24 June 2021. Retrieved 17 June 2021.
  74. ^ a b c d e f g h i j k l m n o p q r s "3,4-Methylenedioxymethamphetamine". Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Archived from the original on 4 April 2019. Retrieved 22 August 2014.
  75. ^ a b c d e f g Keane M (February 2014). "Recognising and managing acute hyponatraemia". Emergency Nurse. 21 (9): 32–6, quiz 37. doi:10.7748/en2014.02.21.9.32.e1128. PMID 24494770.
  76. ^ a b c d e f White CM (March 2014). "How MDMA's pharmacology and pharmacokinetics drive desired effects and harms". Journal of Clinical Pharmacology. 54 (3): 245–52. doi:10.1002/jcph.266. PMID 24431106. S2CID 6223741.
  77. ^ Spauwen LW, Niekamp AM, Hoebe CJ, Dukers-Muijrers NH (February 2015). "Drug use, sexual risk behaviour and sexually transmitted infections among swingers: a cross-sectional study in The Netherlands". Sexually Transmitted Infections. 91 (1): 31–6. doi:10.1136/sextrans-2014-051626. PMID 25342812. It is known that some recreational drugs (eg, MDMA or GHB) may hamper the potential to ejaculate or maintain an erection.
  78. ^ Hahn IH (25 March 2015). "MDMA Toxicity: Background, Pathophysiology, Epidemiology". Medscape. Archived from the original on 11 May 2016. Retrieved 14 May 2016.
  79. ^ Parrott AC (2012). "13. MDMA and LSD". In Verster J, Brady K, Galanter M, Conrod P (eds.). Drug Abuse and Addiction in Medical Illness: Causes, Consequences and Treatment. Springer Science & Business Media. p. 179. ISBN 978-1-4614-3375-0.
  80. ^ Alvarenga TA, Andersen ML, Ribeiro DA, Araujo P, Hirotsu C, Costa JL, et al. (January 2010). "Single exposure to cocaine or ecstasy induces DNA damage in brain and other organs of mice". Addiction Biology. 15 (1): 96–99. doi:10.1111/j.1369-1600.2009.00179.x. PMID 19878142. S2CID 21347765.
  81. ^ Alvarenga TA, Ribeiro DA, Araujo P, Hirotsu C, Mazaro-Costa R, Costa JL, et al. (September 2011). "Sleep loss and acute drug abuse can induce DNA damage in multiple organs of mice". Human & Experimental Toxicology. 30 (9): 1275–1281. Bibcode:2011HETox..30.1275A. doi:10.1177/0960327110388535. PMID 21071548. S2CID 25477893.
  82. ^ Frenzilli G, Ferrucci M, Giorgi FS, Blandini F, Nigro M, Ruggieri S, et al. (September 2007). "DNA fragmentation and oxidative stress in the hippocampal formation: a bridge between 3,4-methylenedioxymethamphetamine (ecstasy) intake and long-lasting behavioral alterations". Behavioural Pharmacology. 18 (5–6): 471–481. doi:10.1097/FBP.0b013e3282d518aa. PMID 17762515. S2CID 38285923.
  83. ^ a b c d e f g h Garg A, Kapoor S, Goel M, Chopra S, Chopra M, Kapoor A, et al. (2015). "Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review". Current Drug Abuse Reviews. 8 (1): 15–25. doi:10.2174/1874473708666150303115833. PMID 25731754.
  84. ^ a b Mueller F, Lenz C, Steiner M, Dolder PC, Walter M, Lang UE, et al. (March 2016). "Neuroimaging in moderate MDMA use: A systematic review". Neuroscience and Biobehavioral Reviews. 62: 21–34. doi:10.1016/j.neubiorev.2015.12.010. PMID 26746590.
  85. ^ Gouzoulis-Mayfrank E, Daumann J (2009). "Neurotoxicity of drugs of abuse--the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines". Dialogues in Clinical Neuroscience. 11 (3): 305–17. doi:10.31887/DCNS.2009.11.3/egmayfrank. PMC 3181923. PMID 19877498.
  86. ^ a b Halpin LE, Collins SA, Yamamoto BK (February 2014). "Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine". Life Sciences. 97 (1): 37–44. doi:10.1016/j.lfs.2013.07.014. PMC 3870191. PMID 23892199. In contrast, MDMA produces damage to serotonergic, but not dopaminergic axon terminals in the striatum, hippocampus, and prefrontal cortex (Battaglia et al., 1987, O'Hearn et al., 1988). The damage associated with Meth and MDMA has been shown to persist for at least 2 years in rodents, non-human primates and humans (Seiden et al., 1988, Woolverton et al., 1989, McCann et al., 1998, Volkow et al., 2001a, McCann et al., 2005)
  87. ^ Szigeti B, Winstock AR, Erritzoe D, Maier LJ (July 2018). "Are ecstasy induced serotonergic alterations overestimated for the majority of users?". Journal of Psychopharmacology. 32 (7): 741–748. doi:10.1177/0269881118767646. PMID 29733742. S2CID 13660975. Given the dose-response relationship between MDMA exposure and SERT reductions and the statistically non-significant SERT binding differences for users with use levels similar to the majority of real-life users, it can be speculated that SERT levels may not be significantly affected for most recreational ecstasy users.
  88. ^ Roberts CA, Jones A, Montgomery C (April 2016). "Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users". Neuroscience and Biobehavioral Reviews. 63: 158–67. doi:10.1016/j.neubiorev.2016.02.003. PMID 26855234.
  89. ^ a b c d e f Parrott AC (2014). "The potential dangers of using MDMA for psychotherapy". Journal of Psychoactive Drugs. 46 (1): 37–43. doi:10.1080/02791072.2014.873690. PMID 24830184. S2CID 23485480.
  90. ^ Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, et al. (January 2009). "The harmful health effects of recreational ecstasy: a systematic review of observational evidence". Health Technology Assessment. 13 (6): iii–iv, ix–xii, 1–315. doi:10.3310/hta13050. hdl:10871/11534. PMID 19195429.
  91. ^ Kuypers KP, Theunissen EL, van Wel JH, de Sousa Fernandes Perna EB, Linssen A, Sambeth A, et al. (2016). "Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective". PLOS ONE. 11 (2): e0149438. Bibcode:2016PLoSO..1149438K. doi:10.1371/journal.pone.0149438. PMC 4764468. PMID 26907605.
  92. ^ Laws KR, Kokkalis J (August 2007). "Ecstasy (MDMA) and memory function: a meta-analytic update". Human Psychopharmacology. 22 (6): 381–8. doi:10.1002/hup.857. PMID 17621368. S2CID 25353240.
  93. ^ Kousik SM, Napier TC, Carvey PM (2012). "The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation". Frontiers in Pharmacology. 3: 121. doi:10.3389/fphar.2012.00121. PMC 3386512. PMID 22754527.
  94. ^ McMillan B, Starr C (2014). Human biology (10th ed.). Belmont, CA: Brooks/Cole Cengage Learning. ISBN 978-1-133-59916-6.
  95. ^ Boyle NT, Connor TJ (September 2010). "Methylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern?". British Journal of Pharmacology. 161 (1): 17–32. doi:10.1111/J.1476-5381.2010.00899.X. PMC 2962814. PMID 20718737.
  96. ^ Cavero I, Guillon JM (2014). "Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy". Journal of Pharmacological and Toxicological Methods. 69 (2): 150–161. doi:10.1016/j.vascn.2013.12.004. PMID 24361689.
  97. ^ Padhariya K, Bhandare R, Canney D, Velingkar V (2017). "Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists". Cardiovascular & Hematological Disorders Drug Targets. 17 (2): 86–104. doi:10.2174/1871529X17666170703115111. PMID 28676029.
  98. ^ Koczor CA, Ludlow I, Hight RS, Jiao Z, Fields E, Ludaway T, et al. (November 2015). "Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart". Toxicological Sciences. 148 (1): 183–191. doi:10.1093/toxsci/kfv170. PMC 4731408. PMID 26251327.
  99. ^ Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–1053. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831. S2CID 5903121.
    Lay summary: "Scientists want new drug rankings". BBC News. 23 March 2007. Archived from the original on 2 December 2007. Retrieved 4 April 2008.
  100. ^ a b Olausson P, Jentsch JD, Tronson N, Neve RL, Nestler EJ, Taylor JR (September 2006). "DeltaFosB in the nucleus accumbens regulates food-reinforced instrumental behavior and motivation". The Journal of Neuroscience. 26 (36): 9196–204. doi:10.1523/JNEUROSCI.1124-06.2006. PMC 6674495. PMID 16957076.
  101. ^ a b Robison AJ, Nestler EJ (October 2011). "Transcriptional and epigenetic mechanisms of addiction". Nature Reviews. Neuroscience. 12 (11): 623–37. doi:10.1038/nrn3111. PMC 3272277. PMID 21989194.
  102. ^ Mack AH, Brady KT, Miller SI, Frances RJ (12 May 2016). Clinical Textbook of Addictive Disorders. Guilford Publications. p. 169. ISBN 978-1-4625-2169-2. MDMA's addictive liability appears to be lower than that of other drugs of abuse....
  103. ^ Favrod-Coune T, Broers B (July 2010). "The Health Effect of Psychostimulants: A Literature Review". Pharmaceuticals. 3 (7): 2333–2361. doi:10.3390/ph3072333. PMC 4036656. PMID 27713356. It seems to present a smaller addiction potential than cocaine or methamphetamine.
  104. ^ Ries R, Miller SC, Fiellin DA (2009). Principles of addiction medicine (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 226. ISBN 978-0-7817-7477-2. Archived from the original on 13 January 2023. Retrieved 11 January 2017. MDA and MDMA are less reinforcing than amphetamine...
  105. ^ a b Steinkellner T, Freissmuth M, Sitte HH, Montgomery T (January 2011). "The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine". Biological Chemistry. 392 (1–2): 103–15. doi:10.1515/BC.2011.016. PMC 4497800. PMID 21194370. ...approximately 15% of routine MDMA users recently fit the diagnostic criteria for MDMA dependence according to the Diagnostic and Statistical Manual, fourth edition/DSMIV.
  106. ^ Mack AH, Brady KT, Miller SI, Frances RJ (12 May 2016). Clinical Textbook of Addictive Disorders. Guilford Publications. p. 171. ISBN 978-1-4625-2169-2. Archived from the original on 19 January 2023. Retrieved 13 October 2020. There are no known pharmacological treatments for MDMA addiction.
  107. ^ Vorhees CV (November 1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins". Drug and Chemical Toxicology. 20 (4): 387–99. doi:10.3109/01480549709003895. PMID 9433666.
  108. ^ a b Meamar R, Karamali F, Sadeghi HM, Etebari M, Nasr-Esfahani MH, Baharvand H (June 2010). "Toxicity of ecstasy (MDMA) towards embryonic stem cell-derived cardiac and neural cells". Toxicology in Vitro. 24 (4): 1133–8. Bibcode:2010ToxVi..24.1133M. doi:10.1016/j.tiv.2010.03.005. PMID 20230888. In summary, MDMA is a moderate teratogen that could influence cardiac and neuronal differentiation in the ESC model and these results are in concordance with previous in vivo and in vitro models.
  109. ^ Singer LT, Moore DG, Fulton S, Goodwin J, Turner JJ, Min MO, et al. (2012). "Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy". Neurotoxicology and Teratology. 34 (3): 303–10. Bibcode:2012NTxT...34..303S. doi:10.1016/j.ntt.2012.02.001. PMC 3367027. PMID 22387807.
  110. ^ Lipton JW, Tolod EG, Thompson VB, Pei L, Paumier KL, Terpstra BT, et al. (October 2008). "3,4-Methylenedioxy-N-methamphetamine (ecstasy) promotes the survival of fetal dopamine neurons in culture". Neuropharmacology. 55 (5): 851–859. doi:10.1016/j.neuropharm.2008.06.062. PMC 2572681. PMID 18655796.
  111. ^ a b c d e f Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ (May 2015). "Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review". Drug Alcohol Depend. 150: 1–13. doi:10.1016/j.drugalcdep.2015.01.040. PMID 25724076.
  112. ^ a b Hysek C, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, et al. (August 2012). "Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans". Br J Pharmacol. 166 (8): 2277–2288. doi:10.1111/j.1476-5381.2012.01936.x. PMC 3448893. PMID 22404145.
  113. ^ Vanattou-Saïfoudine N, McNamara R, Harkin A (November 2012). "Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators". British Journal of Pharmacology. 167 (5): 946–59. doi:10.1111/j.1476-5381.2012.02065.x. PMC 3492978. PMID 22671762.
  114. ^ Hall AP, Henry JA (June 2006). "Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management". British Journal of Anaesthesia. 96 (6): 678–85. doi:10.1093/bja/ael078. PMID 16595612.
  115. ^ a b c de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, et al. (April 2004). "Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition". Therapeutic Drug Monitoring. 26 (2): 137–44. doi:10.1097/00007691-200404000-00009. PMID 15228154. It is known that some recreational drugs (e.g., MDMA or GHB) may hamper the potential to ejaculate or maintain an erection.
  116. ^ a b c d e f Kellum JA, Gunn SR, Singer M (2008). Oxford American Handbook of Critical Care. Oxford University Press. p. 464. ISBN 978-0-19-530528-9. OCLC 1003197730.
  117. ^ de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, et al. (April 2004). "Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition". Therapeutic Drug Monitoring. 26 (2): 137–44. doi:10.1097/00007691-200404000-00009. PMID 15228154.
  118. ^ Chummun H, Tilley V, Ibe J (2010). "3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition". British Journal of Nursing. 19 (2): 94–100. PMID 20235382.
  119. ^ Pendergraft WF, Herlitz LC, Thornley-Brown D, Rosner M, Niles JL (November 2014). "Nephrotoxic effects of common and emerging drugs of abuse". Clinical Journal of the American Society of Nephrology. 9 (11): 1996–2005. doi:10.2215/CJN.00360114. PMC 4220747. PMID 25035273.
  120. ^ Silins E, Copeland J, Dillon P (August 2007). "Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk". The Australian and New Zealand Journal of Psychiatry. 41 (8): 649–55. doi:10.1080/00048670701449237. PMID 17620161. S2CID 25832516.
  121. ^ Papaseit E, Pérez-Mañá C, Torrens M, Farré A, Poyatos L, Hladun O, et al. (May 2020). "MDMA interactions with pharmaceuticals and drugs of abuse". Expert Opin Drug Metab Toxicol. 16 (5): 357–369. doi:10.1080/17425255.2020.1749262. PMID 32228243. S2CID 214750903.
  122. ^ a b c d e f g h i j k l Fonseca DA, Ribeiro DM, Tapadas M, Cotrim MD (July 2021). "Ecstasy (3,4-methylenedioxymethamphetamine): Cardiovascular effects and mechanisms". Eur J Pharmacol. 903: 174156. doi:10.1016/j.ejphar.2021.174156. PMID 33971177.
  123. ^ a b Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, et al. (April 2015). "Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects". J Pharmacol Exp Ther. 353 (1): 102–111. doi:10.1124/jpet.114.222356. PMID 25655950.
  124. ^ Vuori E, Henry JA, Ojanperä I, Nieminen R, Savolainen T, Wahlsten P, et al. (March 2003). "Death following ingestion of MDMA (ecstasy) and moclobemide". Addiction. 98 (3): 365–8. doi:10.1046/j.1360-0443.2003.00292.x. PMID 12603236.
  125. ^ a b Halberstadt AL, Nichols DE (2020). "Serotonin and serotonin receptors in hallucinogen action". Handbook of the Behavioral Neurobiology of Serotonin. Handbook of Behavioral Neuroscience. Vol. 31. pp. 843–863. doi:10.1016/B978-0-444-64125-0.00043-8. ISBN 9780444641250. ISSN 1569-7339. S2CID 241134396.
  126. ^ a b Mendelson J, Baggott MJ, Li L, Coyle J, Galloway GP (2012). "Poster Session II (PII 1-111): PII-41. MDMA-Induced Increases in Blood Pressure Are Not Mediated by α-Adrenergic Mechanisms and Are Not Due To Elevated Peripheral Vascular Resistance". Clinical Pharmacology & Therapeutics. 91 (S1 [American Society for Clinical Pharmacology and Therapeutics Abstract of papers, 2012 Annual Meeting Gaylord National Hotel and Convention Center National Harbor, Maryland March 14–17, 2012]): S51–S93 (S66–S66). doi:10.1038/clpt.2011.361. ISSN 0009-9236. MDMA increased heart rate (HR) by 25 bpm (p<.001), [cardiac output (CO)] by 1.75 L/min (p<0.01) but did not alter [stroke volume (SV)] or [systemic vascular resistance (SVR)]. Compared to MDMA alone the combination of MDMA + prazosin further increased HR by 24 bpm (p<0.001) and CO by 3.3L/min (p<0.02). MDMA increased systolic and diastolic blood pressure (SBP, DBP) by 26 mmHg (p<0.001 each); prazosin attenuated MDMA effects on DBP by 9.3 mmHg (p<001) but did not alter SBP. [...] MDMA increases HR, producing elevations in CO. The hypertensive effects of MDMA are not due to elevated peripheral vascular resistance and the blood pressure effects of MDMA are not attenuated by α-adrenergic blockade, suggesting that MDMA may produce CV effects through non-α-adrenergic mechanisms.
  127. ^ Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (October 2000). "Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans". Neuropsychopharmacology. 23 (4): 396–404. doi:10.1016/S0893-133X(00)00126-3. PMID 10989266.
  128. ^ Wsół A (December 2023). "Cardiovascular safety of psychedelic medicine: current status and future directions". Pharmacol Rep. 75 (6): 1362–1380. doi:10.1007/s43440-023-00539-4. PMC 10661823. PMID 37874530.
  129. ^ Neumann J, Dhein S, Kirchhefer U, Hofmann B, Gergs U (2024). "Effects of hallucinogenic drugs on the human heart". Front Pharmacol. 15: 1334218. doi:10.3389/fphar.2024.1334218. PMC 10869618. PMID 38370480.
  130. ^ Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, et al. (October 2023). "Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants". Neuropsychopharmacology. 48 (11): 1659–1667. doi:10.1038/s41386-023-01607-2. PMC 10517157. PMID 37231080.
  131. ^ Hart XM, Spangemacher M, Defert J, Uchida H, Gründer G (April 2024). "Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants". Ther Drug Monit. 46 (2): 155–169. doi:10.1097/FTD.0000000000001142. PMID 38287888.
  132. ^ Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, et al. (October 2021). "Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants" (PDF). The World Journal of Biological Psychiatry. 22 (8): 561–628. doi:10.1080/15622975.2021.1878427. PMID 33977870. S2CID 234472488. Archived (PDF) from the original on 5 May 2022. Retrieved 10 April 2022.
  133. ^ Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, et al. (March 2014). "Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination" (PDF). Int J Neuropsychopharmacol. 17 (3): 371–381. doi:10.1017/S1461145713001132. PMID 24103254.
  134. ^ Hysek CM, Vollenweider FX, Liechti ME (August 2010). "Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy)" (PDF). Emerg Med J. 27 (8): 586–589. doi:10.1136/emj.2009.079905. PMID 20378736.
  135. ^ Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, et al. (February 2012). "Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers". J Pharmacol Exp Ther. 340 (2): 286–294. doi:10.1124/jpet.111.188425. PMID 22034656.
  136. ^ Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (October 2013). "α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans". J Clin Psychopharmacol. 33 (5): 658–666. doi:10.1097/JCP.0b013e3182979d32. PMID 23857311.
  137. ^ Liechti ME, Vollenweider FX (July 2000). "Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans". Eur Neuropsychopharmacol. 10 (4): 289–295. doi:10.1016/s0924-977x(00)00086-9. PMID 10871712.
  138. ^ Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo Gómez MM, et al. (May 2017). "β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon". J Cardiovasc Pharmacol Ther. 22 (3): 239–249. doi:10.1177/1074248416681644. PMID 28399647.
  139. ^ "PDSP Database". UNC (in Zulu). Retrieved 11 December 2024.
  140. ^ Liu T. "BindingDB BDBM50010588 (RS)-3,4-(methylenedioxy)methamphetamine::1-(1,3-Benzodioxol-5-yl)-N-methyl-2-propanamine::1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine::3,4-methylenedioxymethamphetamine::CHEMBL43048::DL-(3,4-Methylenedioxy)methamphetamine::MDMA::N,alpha-dimethyl-1,3-benzodioxole-5-ethanamine::N-Methyl-3,4-methylenedioxyamphetamine::US11767305, Compound MDMA". BindingDB. Retrieved 11 December 2024.
  141. ^ Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
  142. ^ Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. (January 2013). "Pharmacological characterization of designer cathinones in vitro". Br J Pharmacol. 168 (2): 458–470. doi:10.1111/j.1476-5381.2012.02145.x. PMC 3572571. PMID 22897747.
  143. ^ Simmler LD, Rickli A, Hoener MC, Liechti ME (April 2014). "Monoamine transporter and receptor interaction profiles of a new series of designer cathinones". Neuropharmacology. 79: 152–160. doi:10.1016/j.neuropharm.2013.11.008. PMID 24275046.
  144. ^ Rickli A, Kopf S, Hoener MC, Liechti ME (July 2015). "Pharmacological profile of novel psychoactive benzofurans". Br J Pharmacol. 172 (13): 3412–3425. doi:10.1111/bph.13128. PMC 4500375. PMID 25765500.
  145. ^ Luethi D, Kolaczynska KE, Walter M, Suzuki M, Rice KC, Blough BE, et al. (July 2019). "Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems". J Psychopharmacol. 33 (7): 831–841. doi:10.1177/0269881119844185. PMC 8269116. PMID 31038382.
  146. ^ Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601.
  147. ^ Sotnikova TD, Caron MG, Gainetdinov RR (August 2009). "Trace amine-associated receptors as emerging therapeutic targets". Mol Pharmacol. 76 (2): 229–235. doi:10.1124/mol.109.055970. PMC 2713119. PMID 19389919.
  148. ^ Underhill S, Amara S (18 April 2020). "MDMA and TAAR1-mediated RhoA Activation in Serotonin Neurons". The FASEB Journal. 34 (1): 1. doi:10.1096/fasebj.2020.34.s1.05856.
  149. ^ Underhill SM, Hullihen PD, Chen J, Fenollar-Ferrer C, Rizzo MA, Ingram SL, et al. (April 2021). "Amphetamines signal through intracellular TAAR1 receptors coupled to Gα13 and GαS in discrete subcellular domains". Molecular Psychiatry. 26 (4): 1208–1223. doi:10.1038/s41380-019-0469-2. PMC 7038576. PMID 31399635.
  150. ^ Lizarraga LE, Cholanians AB, Phan AV, Herndon JM, Lau SS, Monks TJ (January 2015). "Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine". Toxicological Sciences. 143 (1): 209–219. doi:10.1093/toxsci/kfu222. PMC 4274386. PMID 25370842.
  151. ^ Pitts EG, Curry DW, Hampshire KN, Young MB, Howell LL (February 2018). "(±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA". Psychopharmacology. 235 (2): 377–392. doi:10.1007/s00213-017-4812-5. PMID 29248945. S2CID 3343930.
  152. ^ Liechti ME, Vollenweider FX (December 2001). "Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies". Human Psychopharmacology. 16 (8): 589–598. doi:10.1002/hup.348. PMID 12404538. S2CID 45640843.
  153. ^ Halberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior". Curr Top Behav Neurosci. Current Topics in Behavioral Neurosciences. 36: 159–199. doi:10.1007/7854_2016_466. ISBN 978-3-662-55878-2. PMC 5787039. PMID 28224459. [MDxx] have been assessed in head twitch studies. Racemic [MDA] and S-(+)-MDA reportedly induce WDS in monkeys and rats, respectively (Schlemmer and Davis 1986; Hiramatsu et al. 1989). Although [MDMA] does not induce the HTR in mice, both of the stereoisomers of MDMA have been shown to elicit the response (Fantegrossi et al. 2004, 2005b). 5-HT depletion inhibits the response to S-(+)-MDMA but does not alter the response to R-(−)-MDMA, suggesting the isomers act through different mechanisms (Fantegrossi et al. 2005b). This suggestion is consistent with the fact that S-(+)- and R-(−)-MDMA exhibit qualitatively distinct pharmacological profiles, with the S-(+)isomer working primarily as a monoamine releaser (Johnson et al. 1986; Baumann et al. 2008; Murnane et al. 2010) and the R-(−)-enantiomer acting directly through 5-HT2A receptors (Lyon et al. 1986; Nash et al. 1994). In contrast to their effects in mice, Hiramatsu reported that S-(+)- and R-(−)-MDMA fail to produce WDS in rats (Hiramatsu et al. 1989). The discrepant findings with MDMA in mice and rats may reflect species differences in sensitivity to the HTR (see below for further discussion).
  154. ^ Dunlap LE (2022). Development of Non-Hallucinogenic Psychoplastogens (Thesis). University of California, Davis. Retrieved 18 November 2024. Finally, since R-MDMA is known to partially substitute for LSD in animal models we decided to test both compounds in the head twitch response assay (HTR) (FIG 3.3C).3 The HTR is a well-validated mouse model for predicting the hallucinogenic potential of test drugs. Serotonergic psychedelics will cause a rapid back and forth head movement in mice. The potency measured in the HTR assay has been shown to correlate very well with the human potencies of psychedelics.18 Neither R-MDMA or LED produced any head twitches at all doses tested, suggesting that neither has high hallucinogenic potential.
  155. ^ Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
  156. ^ Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, et al. (June 2003). "3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro". Molecular Pharmacology. 63 (6): 1223–1229. doi:10.1124/mol.63.6.1223. PMID 12761331. S2CID 839426.{{cite journal}}: CS1 maint: overridden setting (link)
  157. ^ Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707. S2CID 15573624.
  158. ^ Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (April 2012). "Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters". The Journal of Pharmacology and Experimental Therapeutics. 341 (1): 251–262. doi:10.1124/jpet.111.188946. PMC 3364510. PMID 22271821.
  159. ^ Marusich JA, Antonazzo KR, Blough BE, Brandt SD, Kavanagh PV, Partilla JS, et al. (February 2016). "The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue". Neuropharmacology. 101: 68–75. doi:10.1016/j.neuropharm.2015.09.004. PMC 4681602. PMID 26362361.
  160. ^ Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–137. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
  161. ^ Halberstadt AL, Brandt SD, Walther D, Baumann MH (March 2019). "2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors". Psychopharmacology (Berl). 236 (3): 989–999. doi:10.1007/s00213-019-05207-1. PMC 6848746. PMID 30904940.
  162. ^ Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W.
  163. ^ Mas M, Farré M, de la Torre R, Roset PN, Ortuño J, Segura J, et al. (July 1999). "Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 136–45. PMID 10381769.
  164. ^ a b de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, et al. (February 2000). "Non-linear pharmacokinetics of MDMA ('ecstasy') in humans". British Journal of Clinical Pharmacology. 49 (2): 104–9. doi:10.1046/j.1365-2125.2000.00121.x. PMC 2014905. PMID 10671903.
  165. ^ Farré M, Roset PN, Lopez CH, Mas M, Ortuño J, Menoyo E, et al. (September 2000). "Pharmacology of MDMA in humans". Annals of the New York Academy of Sciences. 914 (1): 225–37. Bibcode:2000NYASA.914..225D. doi:10.1111/j.1749-6632.2000.tb05199.x. PMID 11085324. S2CID 29247621.
  166. ^ a b Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (June 2008). "Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults". Therapeutic Drug Monitoring. 30 (3): 320–32. doi:10.1097/FTD.0b013e3181684fa0. PMC 2663855. PMID 18520604.
  167. ^ Shima N, Kamata H, Katagi M, Tsuchihashi H, Sakuma T, Nemoto N (September 2007). "Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine". Journal of Chromatography B. 857 (1): 123–9. doi:10.1016/j.jchromb.2007.07.003. PMID 17643356.
  168. ^ Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ (July 1999). "Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans". Clinical Chemistry. 45 (7): 1058–69. doi:10.1093/clinchem/45.7.1058. PMID 10388483.
  169. ^ Mueller M, Peters FT, Maurer HH, McCann UD, Ricaurte GA (October 2008). "Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses". The Journal of Pharmacology and Experimental Therapeutics. 327 (1): 38–44. doi:10.1124/jpet.108.141366. PMID 18591215. S2CID 38043715.
  170. ^ Milhazes N, Martins P, Uriarte E, Garrido J, Calheiros R, Marques MP, et al. (July 2007). "Electrochemical and spectroscopic characterisation of amphetamine-like drugs: application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors". Analytica Chimica Acta. 596 (2): 231–41. Bibcode:2007AcAC..596..231M. doi:10.1016/j.aca.2007.06.027. hdl:10316/45124. PMID 17631101.
  171. ^ Milhazes N, Cunha-Oliveira T, Martins P, Garrido J, Oliveira C, Rego AC, et al. (October 2006). "Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship" (PDF). Chemical Research in Toxicology. 19 (10): 1294–304. doi:10.1021/tx060123i. hdl:10316/12872. PMID 17040098. Archived (PDF) from the original on 28 June 2021. Retrieved 24 September 2019.
  172. ^ Baxter EW, Reitz AB (April 2004). "Reductive aminations of carbonyl compounds with borohydride and borane reducing agents". Organic Reactions. 59. Hoboken, New Jersey, United States: 59. doi:10.1002/0471264180.or059.01. ISBN 0471264180.
  173. ^ Gimeno P, Besacier F, Bottex M, Dujourdy L, Chaudron-Thozet H (December 2005). "A study of impurities in intermediates and 3,4-methylenedioxymethamphetamine (MDMA) samples produced via reductive amination routes". Forensic Science International. 155 (2–3): 141–57. doi:10.1016/j.forsciint.2004.11.013. PMID 16226151.
  174. ^ Palhol F, Boyer S, Naulet N, Chabrillat M (September 2002). "Impurity profiling of seized MDMA tablets by capillary gas chromatography". Analytical and Bioanalytical Chemistry. 374 (2): 274–81. doi:10.1007/s00216-002-1477-6. PMID 12324849. S2CID 42666306.
  175. ^ Renton RJ, Cowie JS, Oon MC (August 1993). "A study of the precursors, intermediates and reaction by-products in the synthesis of 3,4-methylenedioxymethylamphetamine and its application to forensic drug analysis". Forensic Science International. 60 (3): 189–202. doi:10.1016/0379-0738(93)90238-6. PMID 7901132.
  176. ^ Mohan J, ed. (June 2014). World Drug Report 2014 (PDF). Vienna, Austria: United Nations Office on Drugs and Crime. pp. 2, 3, 123–152. ISBN 978-92-1-056752-7. Archived (PDF) from the original on 13 November 2014. Retrieved 1 December 2014.
  177. ^ "Early Warning - MDMA and MDA Producers Using Ocotea Cymbarum as a Precursor" (PDF). DEA Microgram Newsletter. 38 (11). Drug Enforcement Agency, U.S. Department of Justice: 166. 11 November 2005. Archived from the original (PDF) on 18 October 2012.
  178. ^ Barnes AJ, De Martinis BS, Gorelick DA, Goodwin RS, Kolbrich EA, Huestis MA (March 2009). "Disposition of MDMA and metabolites in human sweat following controlled MDMA administration". Clinical Chemistry. 55 (3): 454–62. doi:10.1373/clinchem.2008.117093. PMC 2669283. PMID 19168553.
  179. ^ Baselt RC (2011). Disposition of toxic drugs and chemicals in man (9th ed.). Seal Beach, Ca.: Biomedical Publications. pp. 1078–1080. ISBN 978-0-9626523-8-7.
  180. ^ a b c Bernschneider-Reif S, Oxler F, Freudenmann RW (November 2006). "The origin of MDMA ("ecstasy")--separating the facts from the myth". Die Pharmazie. 61 (11): 966–72. PMID 17152992. Archived from the original on 24 September 2015. Retrieved 30 January 2014.
  181. ^ Firma E. Merck in Darmstadt (16 May 1914). "German Patent 274350: Verfahren zur Darstellung von Alkyloxyaryl-, Dialkyloxyaryl- und Alkylendioxyarylaminopropanen bzw. deren am Stickstoff monoalkylierten Derivaten". Kaiserliches Patentamt. Archived from the original on 28 August 2021. Retrieved 12 April 2009.
  182. ^ Firma E. Merck in Darmstadt (15 October 1914). "German Patent 279194: Verfahren zur Darstellung von Hydrastinin Derivaten". Kaiserliches Patentamt. Archived from the original on 28 August 2021. Retrieved 20 July 2009.
  183. ^ Shulgin AT (1990). "1. History of MDMA". In Peroutka SJ (ed.). Ecstasy : the clinical, pharmacological, and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic Publishers. pp. 2, 14. ISBN 978-0-7923-0305-3.
  184. ^ Hardman HF, Haavik CO, Seevers MH (June 1973). "Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals". Toxicology and Applied Pharmacology. 25 (2): 299–309. Bibcode:1973ToxAP..25..299H. doi:10.1016/S0041-008X(73)80016-X. hdl:2027.42/33868. PMID 4197635. Archived from the original on 21 October 2008. Retrieved 19 April 2009.
  185. ^ a b c d e f g h i Benzenhöfer U, Passie T (August 2010). "Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin". Addiction. 105 (8): 1355–61. doi:10.1111/j.1360-0443.2010.02948.x. PMID 20653618.
  186. ^ Biniecki S, Krajewski E (1960). "Production of d,1-N-methyl-beta-(3,4-methylenedioxyphenyl)-isopropylamine and d,1-N-methyl-beta-(3,4-dimthoxyphenyl)-isopropylamine". Acta Polon Pharm (in Polish). 17: 421–5.
  187. ^ a b c Siegel RK (October 1986). "MDMA. Nonmedical use and intoxication" (PDF). Journal of Psychoactive Drugs. 18 (4): 349–54. doi:10.1080/02791072.1986.10472368. PMID 2880950. Archived (PDF) from the original on 4 March 2016. Retrieved 11 August 2015.
  188. ^ The first confirmed sample was seized and identified by Chicago Police in 1970, see Sreenivasan VR (1972). "Problems in Identification of Methylenedioxy and Methoxy Amphetamines". Journal of Criminal Law, Criminology, and Police Science. 63 (2): 304–312. doi:10.2307/1142315. JSTOR 1142315. Archived from the original on 21 October 2008. Retrieved 19 April 2009.
  189. ^ a b Foderaro LW (11 December 1988). "Psychedelic Drug Called Ecstasy Gains Popularity in Manhattan Nightclubs". The New York Times. Archived from the original on 17 November 2015. Retrieved 27 August 2015.
  190. ^ a b c d Brown E (September 2002). "Professor X". Wired. Archived from the original on 25 June 2015. Retrieved 4 January 2015.
  191. ^ a b Beck JE (April 1987). "Drug Abuse Series: MDMA". Erowid. Drug Abuse Information and Monitoring Project. Archived from the original on 4 August 2015. Retrieved 6 August 2015.
  192. ^ a b c d e f g h Pentney AR (2001). "An exploration of the history and controversies surrounding MDMA and MDA". Journal of Psychoactive Drugs. 33 (3): 213–21. doi:10.1080/02791072.2001.10400568. PMID 11718314. S2CID 31142434.
  193. ^ "Alexander 'Sasha' Shulgin". Alexander Shulgin Research Institute. Archived from the original on 20 December 2014. Retrieved 8 January 2015.
  194. ^ a b c d Shulgin AT, Shulgin A (1991). "Chapters 12, 22". PiHKAL: A Chemical Love Story (7th printing, 1st ed.). Berkeley, CA: Transform Press. ISBN 978-0-9630096-0-9.
  195. ^ Shulgin AT, Nichols DE (1978). "Characterization of Three New Psychotomimetics". In Willette RE, Stillman RJ (eds.). The Psychopharmacology of Hallucinogens. New York: Pergamon Press. pp. 74–83. ISBN 978-0-08-021938-7. Archived from the original on 15 May 2013. Retrieved 4 January 2015.
  196. ^ a b c d Bennett D (30 January 2005). "Dr. Ecstasy". The New York Times Magazine. Archived from the original on 17 November 2011. Retrieved 10 February 2017.
  197. ^ a b c d e f Jennings P (1 April 2004). "Ecstasy Rising". Primetime Thursday. No. Special edition. ABC News. Archived from the original on 27 May 2015.
  198. ^ Shulgin A (2004). "Tribute to Jacob" (PDF). In Doblin R (ed.). The Secret Chief Revealed (2nd ed.). Sarasota, Fl: Multidisciplinary Association for Psychedelic Studies. pp. 17–18. ISBN 978-0-9660019-6-9. Archived from the original (PDF) on 16 September 2018. Retrieved 7 January 2015.
  199. ^ a b "Ecstasy on Prescription". BBC Business Daily. 29 May 2018. Archived from the original on 10 July 2021. Retrieved 10 July 2021.
  200. ^ Milroy CM (February 1999). "Ten years of 'ecstasy'". Journal of the Royal Society of Medicine. 92 (2): 68–72. doi:10.1177/014107689909200206. PMC 1297063. PMID 10450215.
  201. ^ a b c d e f g h Eisner B (1994). Ecstasy : The MDMA Story (Expanded 2nd ed.). Berkeley, CA: Ronin Publishing. ISBN 978-0-914171-68-3. Archived from the original on 13 January 2023. Retrieved 1 February 2016.
  202. ^ a b c d e f g h i j k l m n Beck J, Rosenbaum M (1994). "The Distribution of Ecstasy". Pursuit of Ecstasy : The MDMA Experience. Albany: State Univ. of New York Press. ISBN 978-0-7914-1817-8.
  203. ^ a b c d Doblin R, Rosenbaum M (1991). "Chapter 6: Why MDMA Should Not Have Been Made Illegal" (PDF). In Inciardi JA (ed.). The Drug Legalization Debate (2nd ed.). London: SAGE Publications, Inc. ISBN 978-0-8039-3678-2. Retrieved 10 August 2015.
  204. ^ Collin M, Godfrey J (2010). "The Technologies of Pleasure". Altered State: The Story of Ecstasy Culture and Acid House (Updated new ed.). London: Profile Books. ISBN 978-1-84765-641-4.
  205. ^ Savlov M (12 June 2000). "Countdown to Ecstasy: A New Drug for a New Millennium". The Austin Chronicle. Weekly Wire. Archived from the original on 21 January 2016. Retrieved 6 August 2015.
  206. ^ Owen F, Gavin L (20 October 2013). "Molly Isn't Who You Think She Is: A Deeper Look at MDMA". Playboy. Archived from the original on 27 July 2015. Retrieved 6 August 2015.
  207. ^ Sylvan R (2005). "A Brief History of the Rave Scene". Trance Formation: The Spiritual and Religious Dimensions of Global Rave Culture. New York, NY: Routledge. pp. 21–22. ISBN 978-0-415-97090-7.
  208. ^ Parrott AC (May 2004). "Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity" (PDF). Psychopharmacology. 173 (3–4): 234–41. doi:10.1007/s00213-003-1712-7. PMID 15007594. S2CID 3347303. Archived (PDF) from the original on 18 September 2015. Retrieved 7 August 2015.
  209. ^ Renfroe CL (October 1986). "MDMA on the street: Analysis Anonymous". Journal of Psychoactive Drugs. 18 (4): 363–9. doi:10.1080/02791072.1986.10472371. PMID 2880953.
  210. ^ "Schedules of Controlled Substances Proposed Placement of 3,4-Methylenedioxymethamphetamine in Schedule I" (PDF). Federal Register. 49 (146): 30210. 27 July 1984. Archived (PDF) from the original on 4 March 2016. Retrieved 15 January 2015.
  211. ^ Adler J, Abramson P, Katz S, Hager M (15 April 1985). "Getting High on 'Ecstasy'" (PDF). Newsweek Magazine. Life/Style. p. 96. Archived (PDF) from the original on 20 April 2016. Retrieved 1 February 2015.
  212. ^ a b c Holland J (2001). "The History of MDMA". In Holland J (ed.). Ecstasy: the complete guide; a comprehensive look at the risks and benefits of MDMA. Rochester, VT: Park Street Press. ISBN 978-0-89281-857-0.
  213. ^ a b "U.S. will ban 'ecstasy,' a hallucinogenic drug". The New York Times. The Associated Press. 1 June 1985. Archived from the original on 24 May 2015. Retrieved 29 April 2015.
  214. ^ "MDMA – FDA REPORT, 1985". Erowid. Food and Drug Administration. 1985. Archived from the original on 11 August 2015. Retrieved 11 August 2015.
  215. ^ Baker K (30 May 1985). "DEA To Ban "Ecstasy" – The Drug MDMA". The Associated Press. Archived from the original on 31 August 2018. Retrieved 7 August 2015.
  216. ^ Corwin M (31 May 1985). "U.S. to Ban Use of Drug MDMA : Street Abuse Cited; Used by Psychiatrists". Los Angeles Times. Archived from the original on 17 November 2015. Retrieved 11 August 2015.
  217. ^ Weber B (7 June 2014). "Alexander Shulgin, Psychedelia Researcher, Dies at 88". The New York Times. Archived from the original on 5 September 2015. Retrieved 28 August 2015.
  218. ^ Vastag B (3 June 2014). "Chemist Alexander Shulgin, popularizer of the drug Ecstasy, dies at 88". The Washington Post. WP Company LLC. Archived from the original on 5 August 2015. Retrieved 28 August 2015.
  219. ^ "Ecstasy has its pros and cons". Kokomo Tribune. Kokomo, Indiana. Harper's Bazaar. 23 November 1985. p. 6. Archived from the original on 28 August 2021. Retrieved 9 September 2017 – via newspaperarchive.com. Free access icon
  220. ^ "Lester Grinspoon, M.d., Petitioner, v. Drug Enforcement Administration, Respondent, 828 F.2d 881 (1st Cir. 1987)". Justia Law. US Court of Appeals for the First Circuit. Archived from the original on 9 October 2021. Retrieved 9 October 2021.
  221. ^ Halvorsen JØ, Naudet F, Cristea IA (October 2021). "Challenges with benchmarking of MDMA-assisted psychotherapy" (PDF). Nature Medicine. 27 (10): 1689–1690. doi:10.1038/s41591-021-01525-0. PMID 34635857. S2CID 238636360. Archived (PDF) from the original on 22 May 2022. Retrieved 9 May 2022.
  222. ^ WHO Expert Committee on Drug Dependence: Twenty-second Report (PDF). Geneva: World Health Organization. 1985. pp. 24–25. ISBN 978-9241207294. Archived from the original (PDF) on 19 October 2014. Retrieved 29 August 2012.
  223. ^ "Decision to place MDMA into Schedule I" (PDF). UNODC. Commission on Narcotic Drugs. 11 February 1986. Archived (PDF) from the original on 22 September 2015. Retrieved 9 May 2015.
  224. ^ McKinley JC (12 September 2013). "Overdoses of 'Molly' Led to Electric Zoo Deaths". The New York Times. Archived from the original on 4 December 2013. Retrieved 9 December 2013.
  225. ^ Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE (2011). Goldfrank's toxicologic emergencies (9th ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-160593-9.
  226. ^ "Bibliography of Psychedelic Research Studies". Multidisciplinary Association for Psychedelic Studies (MAPS). Santa Cruz, CA. Archived from the original on 3 December 2013.
  227. ^ James SD (23 February 2015). "What Is Molly and Why Is It Dangerous?". NBCNews.com. Archived from the original on 24 February 2015. Retrieved 23 February 2015. Why is it called Molly? That's short for "molecule." "You can put a ribbon and bow on it and call it a cute name like 'Molly' and people are all in," said Paul Doering, professor emeritus of pharmacology at the University of Florida.
  228. ^ Aleksander I (21 June 2013). "Molly: Pure, but Not So Simple". The New York Times. Archived from the original on 1 January 2022. Retrieved 24 February 2015.
  229. ^ "Mephedrone (4-Methylmethcathinone) appearing in "Ecstasy" in the Netherlands". 19 September 2010. Archived from the original on 5 November 2012. Retrieved 31 December 2012.
  230. ^ "Why ecstasy is 'vanishing' from UK nightclubs". BBC News. 19 January 2010. Archived from the original on 7 September 2017. Retrieved 14 February 2010.
  231. ^ Bish J (4 August 2017). "Watch Out for Pentylone, the Horrible New MDMA Additive". Vice. Archived from the original on 1 September 2020. Retrieved 31 May 2018.
  232. ^ "Annual prevalence of use of drugs, by region and globally, 2016". World Drug Report 2018. United Nations Office on Drugs and Crime. 2018. Retrieved 7 July 2018.
  233. ^ "MDMA and psilocybin: What GPs need to know". Newsgp. Archived from the original on 13 June 2023. Retrieved 13 June 2023.
  234. ^ Bedi G (29 March 2018). "Is psychiatry ready for medical MDMA?". The Conversation. Archived from the original on 4 January 2023. Retrieved 12 April 2024.
  235. ^ "Misuse of Drugs Act 1981". The Government of Western Australia. Department of the Premier and Cabinet. 23 October 1981. Archived from the original on 18 August 2016. Retrieved 22 July 2016.
  236. ^ "ACT government decriminalises small amounts of illicit drugs including speed, heroin and cocaine". ABC News. Australian Broadcasting Corporation. 20 October 2022. Archived from the original on 13 June 2023. Retrieved 13 June 2023.
  237. ^ Roy T (27 October 2023). "The ACT has today decriminalised small amounts of some illicit drugs. But what does that mean?". ABC News. Retrieved 7 June 2024.
  238. ^ Power M (2013). Drugs 2.0 : the web revolution that's changing how the world gets high (epub file). London: Portobello. ISBN 978-1-84627-459-6.
  239. ^ "Misuse of Drugs Act 1971". Statutelaw.gov.uk. 5 January 1998. Archived from the original on 28 August 2021. Retrieved 11 June 2011.
  240. ^ Hope C (7 February 2009). "Ecstasy 'no more dangerous than horse riding'". Telegraph.co.uk. Archived from the original on 10 December 2015. Retrieved 4 December 2015.
  241. ^ Nutt DJ (January 2009). "Equasy-- an overlooked addiction with implications for the current debate on drug harms". Journal of Psychopharmacology. 23 (1): 3–5. doi:10.1177/0269881108099672. PMID 19158127. S2CID 32034780.
  242. ^ Johnson A (2 November 2009). "Why Professor David Nutt was shown the door". The Guardian. London. Archived from the original on 18 January 2014. Retrieved 3 November 2009.
  243. ^ Schedules of Controlled Substances; Scheduling of 3,4-Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act; Remand, 53 Fed. Reg. 5,156 (DEA 22 February 1988).
  244. ^ "Court Rejects Harsh Federal Drug Sentencing Guideline as Scientifically Unjustified". American Civil Liberties Union. 15 July 2011. Archived from the original on 14 March 2014. Retrieved 29 August 2012.
  245. ^ a b Hennig AC (2014). "An Examination of Federal Sentencing Guidelines' Treatment of MDMA ('Ecstasy')". Belmont Law Review. 1: 267. SSRN 2481227.
  246. ^ "Rapport Drugs in Lijsten". Rijksoverheid.nl. 27 June 2011. Archived from the original on 6 March 2012. Retrieved 29 August 2012.
  247. ^ "Committee: the current system of the Opium Act does not have to be changed". government.nl. 24 June 2011. Archived from the original on 29 April 2012. Retrieved 29 August 2012.
  248. ^ "Schedule I". Controlled Drugs and Substances Act. Isomer Design. Archived from the original on 10 November 2013. Retrieved 9 December 2013.
  249. ^ "Definitions and interpretations". Controlled Drugs and Substances Act. Isomer Design. Archived from the original on 10 November 2013. Retrieved 9 December 2013.
  250. ^ "Decriminalizing people who use drugs in B.C." Government of BC. Government Communications and Public Engagement. Archived from the original on 9 March 2023. Retrieved 8 March 2023.
  251. ^ "B.C. recorded 211 toxic drug deaths — almost 7 a day — in January, coroner reports". CBC.ca. 7 March 2023. Archived from the original on 8 March 2023. Retrieved 8 March 2023.
  252. ^ a b "Statistical Bulletin 2018 — prevalence of drug use". European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Archived from the original on 31 December 2018. Retrieved 5 February 2019.
  253. ^ Wu P, Liu X, Pham TH, Jin J, Fan B, Jin Z (November 2010). "Ecstasy use among US adolescents from 1999 to 2008". Drug and Alcohol Dependence. 112 (1–2): 33–8. doi:10.1016/j.drugalcdep.2010.05.006. PMC 2967577. PMID 20570447.
  254. ^ European Monitoring Centre for Drugs and Drug Addiction (2008). Annual report: the state of the drugs problem in Europe (PDF). Luxembourg: Office for Official Publications of the European Communities. p. 49. ISBN 978-92-9168-324-6. Archived from the original (PDF) on 25 April 2013. Retrieved 1 December 2008.
  255. ^ European Monitoring Centre for Drugs Drug Addiction (2014). "Ecstasy: high purity powder available". European Drug Report (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). p. 26. doi:10.2810/32306. ISBN 978-92-9168-694-0. Archived from the original (PDF) on 7 September 2014. Retrieved 4 June 2014.
  256. ^ "Ecstasy-type substances Retail and wholesale prices* and purity levels, by drug, region and country or territory". United Nations Office on Drugs and Crime. Archived from the original on 8 December 2015. Retrieved 2 January 2015.
  257. ^ Camargo J, Esseiva P, González F, Wist J, Patiny L (November 2012). "Monitoring of illicit pill distribution networks using an image collection exploration framework". Forensic Science International. 223 (1–3): 298–305. doi:10.1016/j.forsciint.2012.10.004. PMID 23107059. Archived from the original on 28 August 2021. Retrieved 9 December 2013.
  258. ^ Dillon P. "10 years of ecstasy and other party drug use in Australia: What have we done and what is there left to do?". Drugtext.org. Archived from the original on 9 February 2012.
  259. ^ "Erowid MDMA Vault : Images". Archived from the original on 6 March 2016. Retrieved 3 March 2016.
  260. ^ Cork T (31 July 2015). "Now sick dealers peddle Shaun the Sheep Ecstasy tablets". Western Daily Press. Archived from the original on 12 August 2015. Retrieved 3 March 2016.
  261. ^ Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA (September 2020). "Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies". CNS Drugs (Systematic review). 34 (9): 925–946. doi:10.1007/s40263-020-00748-y. PMC 7447679. PMID 32803732.
  262. ^ Battaglia G, Yeh SY, De Souza EB (February 1988). "MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons". Pharmacology, Biochemistry, and Behavior. 29 (2): 269–274. doi:10.1016/0091-3057(88)90155-4. PMID 2452449.
  263. ^ Bhide NS, Lipton JW, Cunningham JI, Yamamoto BK, Gudelsky GA (August 2009). "Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain". Brain Research. 1286: 32–41. doi:10.1016/j.brainres.2009.06.042. PMC 2754382. PMID 19555677.
  264. ^ Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R (12 September 2019). "Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline". Frontiers in Psychiatry. 10: 650. doi:10.3389/fpsyt.2019.00650. PMC 6751381. PMID 31572236.
  265. ^ Chaliha D, Mamo JC, Albrecht M, Lam V, Takechi R, Vaccarezza M (1 July 2021). "A Systematic Review of the MDMA Model to Address Social Impairment in Autism". Current Neuropharmacology. 19 (7): 1101–1154. doi:10.2174/1570159X19666210101130258. PMC 8686313. PMID 33388021.
  266. ^ Arnovitz MD, Spitzberg AJ, Davani AJ, Vadhan NP, Holland J, Kane JM, et al. (June 2022). "MDMA for the Treatment of Negative Symptoms in Schizophrenia". Journal of Clinical Medicine. 11 (12): 3255. doi:10.3390/jcm11123255. PMC 9225098. PMID 35743326.
Retrieved from "https://en.wikipedia.org/w/index.php?title=MDMA&oldid=1264048937"